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Obesity has reached epidemic proportions in the developed world. The progression from obesity to diabetes mellitus type 2, via
metabolic syndrome, is recognised, and the significant associated increase in the risk of major human cancers acknowledged. We
review themolecular basis of the involvement ofmorbidly high concentrations of endogenous or therapeutic insulin and of insulin-
like growth factors in the progression from obesity to diabetes and finally to cancer. Epidemiological and biochemical studies
establish the role of insulin and hyperinsulinaemia in cancer risk and progression. Insulin-like growth factors, IGF-1 and IGF-2,
secreted by visceral or mammary adipose tissue have significant paracrine and endocrine effects. These effects can be exacerbated
by increased steroid hormone production. Structural studies elucidate how each of the three ligands, insulin, IGF-1, and IGF-2,
interacts differently with isoforms A and B of the insulin receptor and with type I IGF receptor and explain how these protagonists
contribute to diabetes-associated cancer. The above should inform appropriate treatment of cancers that arise in obese individuals
and in those with diabetes mellitus type 2. Novel drugs that target the insulin and insulin-like growth factor signal transduction
pathways are in clinical trial and should be effective if appropriate biomarker-informed patient stratification is implemented.
1. Introduction
The twentieth century was notable for the eradication of
epidemics that had hitherto obliterated large numbers of
mankind. This success was realised through widespread
vaccination, the introduction of effective antibiotics, and
improved nutrition as a result of the implementation of
intensive farming.
Tragically, a new epidemic will guarantee the twenty-first
century an ignominious place in the history of medicine.
As the early twenty-first century has unfolded, obesity in
the developed world has increased dramatically. While many
are aware of the association between obesity and diabetes
because it is reported widely and discussed in the media,
few appreciate the associations between obesity-associated
diabetes and cancer.
This review summarises the biochemistry behind the
physiological response to increased calorie consumption
in the absence of increased calorie expenditure and the
pathological progression through metabolic syndrome to
diabetes mellitus type 2. We examine the evidence for the
associated increase in malignancies and why and how these
malignancies develop and progress. We focus in particular
on the roles of insulin, insulin-like growth factors (IGFs),
and the influence of steroid hormones. We conclude with
a discussion of how knowledge of the biochemical basis of
adiposity- and diabetes-induced cancers should inform the
development and selection of effective drugs with which to
treat cancer patients with a history of adiposity, metabolic
syndrome, and diabetes.
2. The Twenty First Century Epidemic
2.1. Obesity. Our ancestors have roamed the earth for some
four to six million years but obesity has become endemic
only within the last thirty years [1]. The World Health
Organisation estimates that at present one billion people are
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overweight worldwide and that at least 300 million are obese.
The prevalence of obesity continues to rise at an alarming
rate: 26.1% of adults in England are already obese and it is
predicted that 60% of adult men, 50% of adult women, and
25% of children will be clinically obese by 2050 [2].
Obesity is defined most commonly using body mass
index (BMI) which is calculated as an individual’s weight
in kilograms divided by their height in meters squared.
BMI ranges from overweight (BMI 26–30 kg/m2) through
class I (BMI 30–35 kg/m2), class II (BMI 35–40 kg/m2) to
class III (BMI > 40 kg/m2) obesity. The merit of BMI as a
measure of obesity is amatter of debate for several reasons but
mainly because it takes no account of body fat distribution.
In addition, BMI does not differentiate between the relative
contributions to body mass from fat, muscle, or bone. The
BMImeasure overestimates fatness in individuals with a high
muscle mass and underestimates fatness of those with a low
muscle mass.
The cost of obesity in personal and socioeconomic terms
is huge. Obesity increases the risk of a number of conditions
including heart disease, stroke, osteoarthritis, sleep apnoea,
and gout. Moreover, obesity is a powerful risk factor for
diabetes mellitus type 2; it has been estimated that 80% of
patients with diabetesmellitus type 2 are overweight or obese.
2.2. The Importance of Insulin. The pioneering work of Bant-
ing et al. [3] led to the discovery of insulin and identification
of its pivotal role in glucose homeostasis and metabolism
through stimulation of increased glucose uptake by cells and
enhanced conversion of glucose into glycogen for storage.
Insulin has acute metabolic effects, the most important of
which is to reduce blood sugar levels. Glucose levels increase
following a meal, and these high postprandial blood sugar
levels trigger release of insulin from the beta cells of the islets
of Langerhans in the pancreas (Figure 1). In insulin-target
tissues, insulin stimulates translocation of the high affinity
GLUT4 glucose transporters from intracellular storage sites
to the plasma membrane. GLUT4 then transports glucose
into the muscle and liver cells which lowers blood sugar
levels. Higher intracellular glucose concentrations stimulate
increased glycolysis, glycogen synthesis and fatty acid syn-
thesis, decreased gluconeogenesis, glycogenolysis, and fatty
acid oxidation. In fasted individuals, the pancreas secretes
glucagon which mobilises stored energy by stimulation of
glycogenolysis in its target tissues and, in extreme situations,
by neoglycogenesis from amino acids.
2.3. Hyperinsulinaemia and theMetabolic Syndrome. Obesity
develops when energy intake exceeds energy expenditure for
a prolonged time. In response, the body lays down triglyc-
erides as an energy store in adipose tissue. Excess adipose
tissue releases abundant quantities of nonesterified fatty acids
which reach supraphysiological concentrations in the serum.
The high serum concentrations of these fatty acids force liver,
muscle, and other tissues to prioritise oxidation of fats for
energy. As a result, the liver and muscle cells do not absorb,
store, and metabolise glucose in response to insulin stimuli
(Figure 1). Sustained calorie intake results in continuously
high serum glucose concentrations, chronic hyperglycaemia,
in the majority of obese individuals. Absence of a reaction to
insulin secreted by the pancreas in response to the high blood
glucose levelsmeans that the obese individualmanifests resis-
tance to insulin. The development of this insulin resistance
alongside obesity has been classified as metabolic syndrome
(Figure 2). When the fat storage capacity of adipocytes is
exceeded in obese individuals, skeletal muscle, liver and
pancreatic 𝛽-cells are induced to absorb free fatty acids from
serum and to store them as excess fat which drives further
fatty acid oxidation in these cells [4, 5]. Resultant intracellular
metabolites of triglyceride metabolism in the skeletal muscle
and liver cells cause additional insulin resistance.
The metabolic syndrome was identified first in 1988 by
Reaven when he noticed that certain individuals had a col-
lection of risk factors for cardiovascular disease, namely, dys-
lipidaemia, hypertension, and hyperglycaemia [6]. Reaven
termed this collection of risk factors Syndrome X. Subse-
quently called metabolic syndrome, it was defined in 2001
by the Adult Treatment Panel III [7]. They advised that for a
diagnosis of metabolic syndrome, an individual should have
above a threshold level of three of the following five character-
istics: waist circumference, serum triglyceride concentration,
serum high-density lipoprotein (HDL) concentration, blood
pressure, and fasting serum glucose level (Table 1).
2.4. Diabetes Mellitus Type 2 Arises in Obese Individuals.
The metabolic syndrome is a biochemical state that is often
present in the progression from obesity to diabetes. The
combination of reduced glucose metabolism and insulin-
resistance leads to constant hyperglycaemia in the fasting
as well as in the postprandial state. The pancreas secretes
increasingly larger amounts of insulin in an attempt to reduce
the high circulating levels of glucose which results in higher
than normal serum levels of insulin, hyperinsulinaemia.With
time, this excessive insulin production takes its toll on the
pancreas and there is a gradual decline in insulin production
(Figure 2). Hyperglycaemia in obesity with the resultant
continuous insulin production induces metabolic stress in
pancreatic 𝛽-cell mitochondria in the islets of Langerhans.
This stress results in the production of reactive oxygen
species, which damage the mitochondria. As a consequence,
there is decreased 𝛽-cell mitochondrial ATP production and
a reduction in the amount of insulin produced. As well as
𝛽-cell dysfunction, there is a loss in 𝛽-cell mass. Eventually,
the failing mitochondria are no longer able to support the
cell cycle, and apoptosis is induced [8]. Chronic hyper-
glycemia and hyperlipidemia harmdirectly pancreatic𝛽-cells
by two processes referred to as glucotoxicity and lipotoxicity,
respectively. When the 𝛽-cells are exposed continuously to
elevated levels of glucose and fatty acids, these processes
lead to an inhibition of glucose-induced insulin secretion,
impairment of insulin gene expression, and 𝛽-cell apoptosis
[9, 10]. Ectopic storage of triglycerides in pancreatic 𝛽-cells
contributes also to their dysfunction and induces apoptosis
[4, 5].
In the end stages of insulin resistance, when an individual
has developed insulin insufficiency, their inability to control
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Figure 1: Insulin homeostasis in normal and obese individuals. In normal individuals, the postprandial increase in blood glucose
concentration stimulates the beta cells in the Islets of Langerhans of the pancreas to release insulin (a). Insulin stimulates the uptake of
glucose by liver and muscle cells and conversion of glucose to the energy store glycogen primarily in the liver and in skeletal muscle. The
decrease in glucose levels in the blood of fasted individuals stimulates the alpha cells of the Islets of Langerhans in the pancreas to release
glucagon. Glucagon stimulates the conversion of glycogen to glucose by glycogenolysis. In obese individuals, adipocytes in adipose tissue
release nonesterified or free fatty acids (FFAs) energy into the circulation (b). The hepatic portal vein provides a direct conduit of free fatty
acids from visceral adipose tissue to the liver. The high serum concentrations of nonesterified fatty acids force tissues to prioritise their
oxidation as an energy source which prevents glucose uptake. Hence, the obese individual is resistant to the high levels of insulin secreted
after a meal and blood glucose levels remain chronically high regardless of the fed state of the obese individual. The pancreas continues to
secrete insulin in response to the high blood glucose levels. The obese individual manifests hyperglycaemia and hyperinsulinaemia.
normal biochemical glucose levels becomes irreversible. The
obese individual has nowdeveloped chronic diabetesmellitus
type 2 known formerly as noninsulin-dependent diabetes or
adult-onset diabetes.
Diabetes means “to pass through” and refers to the
symptoms of polydypsia and polyuria which are common
symptoms in diabetic patients. More water is passed in the
urine due to the high concentration of glucose in the urine.
Patients become dehydrated and consequently drink more.
The word mellitus means honey sweet and refers to the
sweetness of the urine that results from the presence of
glucose. Diabetesmellitus is a chronic disease of uncontrolled
hyperglycaemia, which is secondary to defects in insulin
secretion, the action of insulin, or both. For a diagnosis
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Figure 2: Progression from obesity throughmetabolic syndrome to diabetes and to increased cancer risk. As an individual’s weight increases,
they progress from having a normal weight to being overweight and with time become obese. There is a concomitant increase in high levels
of circulating nonesterified fatty acids accompanied by high fasting serum glucose concentrations or hyperglycaemia. Many of these obese
individuals exhibit a sufficient number of the defining symptoms to be classified as havingmetabolic syndrome.Thehigh fasting serumglucose
and development of insulin resistance induce chronic secretion of insulin from the pancreas, and the individual manifests hyperinsulinaemia.
Eventually, the excessive demands on the pancreas lead to failure of insulin secretion, and diabetes is established. Diabetic therapies stimulate
insulin secretion or administer exogenous insulin. Insulin concentrations must reach supraphysiological levels to be effective because of the
chronic insulin resistance caused by the continued high concentrations of nonesterified fatty acids released from adipocytes.The combination
of hyperinsulinaemia and endocrine or paracrine stimuli from adipose tissue increases the risk that these individuals will develop certain types
of cancers.
Table 1: Threshold levels to define metabolic syndrome [100].
Characteristic Threshold level
Abdominal obesity
Men >102 cm (40 inches)$
Women >88 cm (35 inches)
Serum HDL
Men >40mg/dL
Women >50mg/dL
Triglycerides ≥150mg/dL
Blood pressure ≥130/85mmHg
Fasting glucose ≥110mg/dL
$Abdominal obesity is given as waist circumference.
of diabetes mellitus in a patient, confirmation of chronic
hyperglycaemia is required [11, 12]. Diabetes mellitus can
be classified into type 1, type 2, gestational, and other
specific types. Diabetes mellitus type 1 develops as a result
of autoimmune or idiopathic destruction of the beta cells
of the pancreas. It is diagnosed most commonly in the
young. Diabetes mellitus type 2 develops due to metabolic
stress-induced beta cell dysfunction or apoptosis as described
above. Gestational diabetes is a diagnosis of any glucose
intolerance detected in pregnancy. The last rare category is
caused by other diseases or specific mutations [12].
Diabetes mellitus type 2 is the most common cause
of diabetes mellitus and accounts for 90% of cases. The
incidence has risen and continues to rise at a rapid rate. It is
estimated that there will be well over 430 million people with
diabetes worldwide by 2030 comparedwith 30million in 1985
and 285 million in 2010.
The World Health Organisation has reported that dia-
betes has become a global epidemic. This review focuses
exclusively on diabetes mellitus type 2, and this type of
diabetes will be referred to simply as diabetes for most of the
remainder of the review.
2.5. Treatment of Diabetes Mellitus Type 2. An unfortunate
consequence of diabetes treatment, which results in part
from the insulin resistance of patients, is chronic or tran-
sient hyperinsulinaemia (Figure 2). Treatment of diabetes
is required to control symptoms and to prevent or slow
progression and consequent organ damage. The overriding
aim is to prevent or reduce hyperglycaemia. Diabetes treat-
ments can be divided into those that increase endogenous
International Journal of Endocrinology 5
insulin secretion, those that decrease insulin resistance, those
that decrease glucose uptake from the intestine, and simple
administration of exogenous insulin.
Secretagogues are a class of drugs which act to increase
endogenous insulin production from the pancreatic beta
cells. They include sulphonylureas and meglitinides. Patients
treated with secretagogues are at risk of hypoglycaemia due
to overproduction of insulin [13].
Biguanides and thiazolidinediones increase insulin sen-
sitivity in peripheral cells. The exact mechanism of action of
the thiazolidinediones is unknown but they increase insulin
sensitivity through direct and indirect effects on muscle and
adipose tissue [14]. Metformin is a biguanide and is the first-
line therapy for the treatment of diabetes mellitus type 2.
The therapeutic effects of metformin are understood only
partially. Metformin activates adenosine monophosphate-
(AMP-) activated protein kinase (AMPK), which leads to
suppression of gluconeogenesis in the liver and increased
peripheral uptake of glucose by skeletal and adipose tissues.
It reduces glucose absorption from the intestine. In addition,
metformin increases the affinity of insulin for the insulin
receptor, which reduces insulin resistance [14].
Acarbose is an alpha glucosidase inhibitor which acts
in the intestinal brush border to prevent the breakdown
of complex carbohydrates to glucose and hence the uptake
of glucose [13]. The incretins and the inhibitors of their
inactivation are a newer group of antihyperglycemic drugs
that slow gastric emptying, increase satiety, and decrease
postprandial glucagon secretion [15].
When oral hyperglycaemic treatments are contraindi-
cated or cease to be effective in patients with diabetes mellitus
type 2, exogenous insulin is given by intramuscular injection.
Relatively large doses of exogenous insulin are required to
overcome the insulin resistance of the peripheral cells [16].
As a result, although diabetes in these patients was caused
by insulin resistance and failure of insulin production as a
direct result of hyperinsulinaemia, treatment with exogenous
insulin causes necessarily hyperinsulinaemia [16].
2.6. Obesity- and Diabetes-Associated Cancer Risk. An esti-
mated 17,294 cases, equivalent to 5.5% of new cancer cases,
occurred in obese individuals in 2010 in theUK.Thenumbers
are similar for the whole of Europe; 3.2% of new cancers
in men and 8.6% of new cancers in women are estimated
to be attributed to obesity [2]. In the United States, 4% of
new cancers in men, 34,000 cancers, and 7% of new cancers
in women, 50,500 cancers, were due to obesity in 2007
(Figure 2) [17]. Direct evidence of the causative impact of
obesity on cancer incidence derives from the demonstration
that for obese individuals the risk is reduced by successful
gastric bypass surgery [18].
The increased risk in the cancers most closely associated
with obesity in men is 1.52 for every additional 5 kg/m2 for
oesophageal, 1.33 for thyroid, and 1.24 for colon and renal.
For women, the increased risk for every additional 5 kg/m2 is
1.59 for endometrial, 1.59 for gall bladder, 1.51 for oesophageal,
and 1.34 for renal cancer (Table 2). Associations are found
for a number of other cancers including pancreas and breast
and colon cancer in women [19]. These cancer types account
for 65% of all new cancers related to obesity [2, 20, 21]. The
percentage of cases attributed to obesity is as high as 40% for
oesophageal and endometrial cancers.
Diabetes is associated with increased risk of certain types
of cancer [22–24] (Figure 2). The increased relative risk for
diabetic individuals compared to nondiabetics is 2.5-fold
for liver, 2.22-fold for endometrial cancer, 1.5–2.0-fold for
pancreatic cancer and non-Hodgkin’s lymphoma, and 1.2–
1.5-fold for biliary tract, renal, bladder, breast and bladder
cancer, and oesophageal adenocarcinoma (Table 2). There is
an increased risk in men with diabetes for oesophageal ade-
nocarcinoma but a reduced risk for oesophageal squamous
cell carcinoma [25]. There is no or inconclusive evidence for
other cancers apart from prostate cancer for which there is a
reduced risk [26].
Although the increased risks associated with obesity and
diabetes may appear relatively small for some cancers, they
translate into a significant number of new cancer cases.
Across 30 European countries, obesity accounts for more
than 124,000 new cancers per year [27], all of which are
potentially avoidable.
2.7. Obesity- and Diabetes-Associated Cancer Progression.
Intuitively, given its role as a risk factor and the putative
mechanisms involved, obesity might be expected to be
associated with worse prognosis in cancer patients. The
evidence from themajority of studies that have addressed this
issue is persuasive. In pancreatic cancer, it has been shown
that increased intra-abdominal fat is associated with shorter
survival [28].
For colon cancer, some studies have found no effect but
others have found obesity to be an independent prognostic
factor associated with a higher mortality, especially in men
[29–31]. For endometrial cancer, 90% of women with the
most common form of endometrial cancer, type I, are
obese [32], and higher BMI is associated with increased
mortality [33]. For epithelial ovarian cancer, a meta-analysis
of observational studies concluded that obesity is associated
with higher mortality [34].
The strongest evidence that obesity is associated with a
poor prognosis is for breast cancer [35]. In a 2002 overview,
the majority of studies found obesity was associated with
increased risk of recurrence and death [36]. A recent large
Danish study found that tumours in obesewomenwere larger
and were more likely to be of a high histological grade and to
have metastasised to lymph nodes [37]. Obese women had
a higher risk of distant metastases and death than nonobese
women. There is some encouragement that prognosis can be
improved by increased physical activity [38, 39].
2.8. Types and Roles of Adipose Tissue. The question arises,
why do individuals who are obese and those who progress
through metabolic syndrome to develop diabetes have an
increased cancer incidence and worse prognosis? To answer
this question, we must consider the biochemical conse-
quences of obesity. The primary roles of adipose tissue have
long been considered to be the storage of energy, thermal
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Table 2: Effects of obesity and diabetes mellitus type 2 on risk of different types of cancer.
Type of cancer Obesity Diabetes mellitus type 2
Men Women Men and women
Bladder None None 1.37 (1.04–1.8) [301]
Breast — — 1.2 (1.11–1.3) [302]
Premenopausal — 0.92 (0.88–0.97) Not available
Postmenopausal — 1.12 (1.08–1.16) Not available
Colorectal — — 1.38 (1.26–1.51) [303]
Colon 1.24 (1.20–1.28) 1.09 (1.05–1.13) Not available
Rectum 1.09 (1.06–1.12) None Not available
Endometrium — 1.59 (1.50–1.68) 2.22 (1.80–2.74) [304]
Gall bladder/biliary tract None 1.59 (1.02–2.47) 1.43 (1.18–1.72) [305]
Liver None None 2.50 (1.80–3.50) [306]
Leukaemia 1.08 (1.02–1.14) 1.17 (1.04–1.32) Not available
Malignant melanoma 1.17 (1.05–1.30) None Not available
Multiple myeloma 1.11 (1.05–1.18) 1.11 (1.07–1.15) Not available
Non-Hodgkin’s lymphoma 1.06 (1.03–1.09) 1.07 (1.00–1.14) 1.79 (1.3–2.47) [307]
Oesophageal adenocarcinoma 1.52 (1.33–1.74) 1.51 (1.31–1.74) 1.3 (1.12–1.50) [25]
Pancreas None 1.12 (1.02–1.22) 1.94 (1.5–2.4) [308]
Renal 1.24 (1.15–1.34) 1.34 (1.25–1.43) 1.42 (1.06–1.91) [309]
Thyroid 1.33 (1.04–1.70) 1.14 (1.06–1.23) Not available
The increased relative risks and the 95% confidence limits, in brackets, are given. For obesity, the relative risk ratio is per 5 kg/m2 increase in weight [19].
regulation, and mechanical protection. More recently, the
role of adipose tissue as an endocrine or metabolic organ has
been recognised. This section examines the different types of
adipose tissue and their impacts on paracrine and endocrine
levels of insulin, IGFs, and steroid hormones.
Adipose tissue is a specialized connective tissue made up
of different cell types, including preadipocytes, adipocytes,
fibroblasts, macrophages, and blood vessels [40], of which
the majority are adipocytes. Approximately 15% of the body
mass of a male of average weight, 70 kg or 11 stone, is adipose
tissue. Adipose tissue is distributed throughout the body. Its
percentage of body mass and pattern of distribution in the
body are influenced by numerous factors including the sex,
age, diet, physical activity level, and genotype of an individual
[41]. In the body, lipids, commonly referred to as fat, are
present usually in the form of triglycerides and make up 80%
of adipose tissue. Although stored largely in adipose tissue,
lipids are found in other tissues especially in pathological
conditions [41]. Triglycerides are present also in the plasma.
The body adapts to the accumulation of increased levels of
triglycerides by hyperplasia and hypertrophy of its adipose
tissue [42].
Adipose tissue can be defined by its biochemical role
[41]. Brown adipose tissue is highly metabolic and utilises
a large amount of glucose. Accordingly, the majority of
the adipocyte cell volume is occupied by large spherical
mitochondria [40], and it is this feature which gives rise
to the brown colour. Brown adipose tissue produces heat
through a specialised metabolic pathway which mobilises
stored energy by breaking down triglycerides to generate heat
energy. Brown adipose tissue is abundant in small animals
and newborns and has been shown to have an important role
in thermal homeostasis in adults.
White adipose tissue is a lipid-rich tissue that has been
considered traditionally as an energy store of excess triglyc-
erides that will be mobilised to release fatty acids when
the body requires more fuel. The discovery of its ability to
function as an endocrine and paracrine organ indicates that
the metabolic role of white adipose tissue is more complex
than appreciated previously [43]. Unlike brown adipocytes,
white adipocytes are spherical cells that contain a single lipid
droplet which accounts for 90% of the cell volume [40].
The mammary gland contains specialized adipose tissue
that is important in epithelial cell growth and milk produc-
tion while bone marrow adipose tissue is known to have a
role in osteogenesis and haematopoiesis [41].
Alternatively, adipose tissue can be classified by its
anatomical positionwhich dichotomises it into subcutaneous
and internal or visceral adipose tissues. Subcutaneous adi-
pose tissue is the adipose tissue that accumulates beneath the
skin. The term “viscera” refers to “organs in the cavity of the
body” [41]. Internal or visceral adipose tissue encases these
body organs.
2.9. Pathological Effects of Different Types of Adipose Tissue.
There is increasing evidence that the anatomical position of
adipose tissue determines the effects that the adipose tissue
has on an individual and predicts the associated morbidity
from cardiovascular disease and diabetes and eventually
cancer [44]. This realisation has led to revised measures of
obesity in addition to BMI. Preferred methods acknowledge
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the relative contributions in obese individuals of different
anatomical types of adipose tissue.
Waist-to-hip ratio (WHR) is used widely to measure
regional adipose tissue distribution because a relatively large
waist measurement indicates that an individual has an excess
of visceral adipose tissue.WHR has been shown to be a better
predictor of subsequent cardiovascular disease and diabetes
than BMI or skin fold thickness [45]. An increasing number
of epidemiological studies use WHR or waist circumference
as more useful measures of obesity [46]. It must be remem-
bered that waist circumference will not be due exclusively to
visceral adipose tissue but also to abdominal subcutaneous
adipose tissue.
Visceral adipose tissue has been shown to have a greater
influence on the development of hypertension and cardio-
vascular disease, and of insulin resistance and diabetes, than
subcutaneous adipose tissue [44, 45]. A study on insulin
sensitivity in obese adults showed that when the data was
adjusted for BMI and visceral adipose tissue, subcutaneous
adipose tissue was protective against development of insulin
resistance. When the data was adjusted for BMI and sub-
cutaneous adipose tissue, increased visceral adipose tissue
was associated with an increase in insulin resistance. The
implication is that visceral adipose tissue promotes insulin
resistance but subcutaneous adipose tissue does not [47].
Multiple reasons have been postulated to explain the
causal effects of visceral adipose tissue on the development
of insulin resistance and cancer. When abdominal visceral
adipose tissue, which is positioned around the liver, enters
a hyperlipolytic state and releases free fatty acids, they
travel through the portal vein to the liver (Figure 1(b)). The
resultant high levels of free fatty acids in the liver impair
hepatic metabolic function which leads to insulin resistance,
hyperinsulinaemia, and hypertriglyceridaemia [48] which
in turn contribute to the development of the metabolic
syndrome. Molecules released by other adipose tissue do not
travel directly to the liver. Inflammatory cells are present
in abundance in visceral adipose tissue and the secretion
of inflammatory mediators into the body creates a chronic
inflammatory state which is thought to generate a protu-
mourigenic environment [49].
The distribution of adipose tissue may explain partially
the variance in the development of the metabolic syndrome
and different types of cancer between men and women
and between different age groups. Visceral adipose tissue
increases with age and weight in both sexes but the progres-
sion is more complicated in females. Overall, females have a
greater percentage bodymass of adipose tissue thanmales but
in premenopausal women, adipose tissue is predominantly
subcutaneous; this is true in obese and in lean individuals
[45]. In men, the majority of adipose tissue is abdominal
visceral adipose tissue.This predominance of visceral adipose
tissue increases with age in a linear fashion. Men have been
shown to have 48% more adipose tissue around the waist
than premenopausal women, of which themajority is visceral
adipose tissue.There is evidence of this sexual dimorphism in
fat patterning even in prepubertal children but the difference
is most marked in young adolescents [50]. The distribution
of adipose tissue changes in postmenopausal women, with an
accumulation of abdominal adipose tissue. It has been found
that postmenopausal women have 49%more visceral adipose
tissue than premenopausal women [51].
2.10. Endocrine Role of Adipose Tissue. The role of adipose
tissue as an endocrine tissue is relevant to the development
of the metabolic syndrome, insulin resistance, diabetes, and
cancer. Adipose tissue has been shown to produce adipokines,
including leptin and adiponectin. Leptin is involved in
the maintenance of normal body weight. Leptin binds the
leptin receptor in the hypothalamus [52, 53] which results
in appetite suppression and increased energy expenditure.
Obese individuals become leptin resistant, and the increased
production of leptin in response to raised food consumption
does not stimulate reduced energy intake or increased energy
expenditure [53, 54]. Elevated levels of circulating leptin
are associated with an increased risk of colorectal [55],
endometrial [56], and in some studies, breast cancer [57].
Increased risk is thought to occur through direct activation
of leptin receptors to induce cell proliferation and reduce
apoptosis [58, 59]. It has been reported that leptin can
influence IGF signal transduction [60] which couldmodulate
the effects of IGFs on cancer risk and progression that are
described below.
Adiponectin acts to sensitive cells to insulin via interac-
tion with the AdipoR1 and AdipoR2 receptors. Activation of
the receptors has also anti-inflammatory effects and increases
fatty acid oxidation which prevents insulin resistance [60].
Whilst the factors that control adiponectin levels are not
defined clearly, levels are lower in obese individuals and
higher levels can be achieved through weight loss [61].
Low levels of adiponectin are associated with an increased
risk of breast, endometrial, prostate, colorectal, and renal
carcinomas [62–65].
Adipose tissue produces also tumour necrosis factor-𝛼,
interleukin-6, angiotensinogen, lipoprotein lipase, plasmino-
gen activator inhibitor-1,monocytic chemoattractant protein,
oestrogens, aromatase, IGFBP-3, IGF-1, and IGF-2 [45]. All of
these molecules may have a role in the complex development
of cancer in obesity. In this review, we concentrate on
the production of IGF-1, IGF-2, IGFBP-3, oestrogens, 17𝛽-
hydroxysteroid dehydrogenase, and aromatase.
2.11. Adiposity and Insulin-Like Growth Factors. Numerous
studies have shown that adipocytes produce IGF-1 and IGF-2
(Figure 3). This production was demonstrated first in animal
studies. For instance, both IGF-1 and IGF-2 mRNAs are
synthesised in rat and porcine adipose tissues [66, 67]. Plasma
IGF-2, but not IGF-1 or IGFBP-3, was associated positively
with back fat depth [68]. Free and total IGF-1 concentrations
measured in serum by enzyme-linked immunosorbent assays
were increased in patients with visceral obesity compared
with nonobese individuals [69]. In vitro models in which
human adipocytes were cultured in chemically defined
culture conditions, demonstrated IGF-1 production from
adipocytes and preadipocytes; production was tenfold higher
from adipocytes than from preadipocytes.
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Figure 3: Adipose tissue as an endocrine organ. Adipocytes express enzymes involved in steroid metabolism, notably 17𝛽-hydroxysteroid
dehydrogenase and aromatase which converts androgens into oestrogens. There is a resultant increase in paracrine concentrations of
oestrogens and a significant increase in the concentration of circulating oestrogens in obese men and in obese postmenopausal women
compared to nonobese individuals. In the blood, oestrogen is complexed with sex hormone-binding globulin (SHBG). Adipocytes secrete
several protein hormones including IGF-1 and IGF-2. IGF-1 and IGF-2 enter the blood streamwhere they can be bound by insulin-like binding
proteins (IGFBPs). Local concentrations of IGF-1 and IGF-2may be particularly high and are unlikely to be reduced by feedbackmechanisms.
Some studies have shown that there are lower serum
IGF-1 concentrations in obesity possibly due to the negative
feedback that the initial rise in serum IGF-1 has on the
production of growth hormone (GH) by the pituitary gland
[70]. A decrease in free GH would reduce stimulation of
hepatocyte production of IGF-1. Although the total levels
of circulating free IGF-1 in the body may be decreased, it
is probable that IGF-1 levels in the adipose tissue remain
higher than normal as a result of the increased production
secondary to adipocyte hyperplasia and hypertrophy. These
local concentrations of IGF-1 may exert significant effects on
surrounding cells and adjacent tissues via paracrine effects
rather than on distant tissue via endocrine mechanisms
(Figure 3). Such local effects could contribute to the observed
greater contribution of visceral adipose tissue to cancer risk
than overall adipose tissue.
2.12. Adiposity and Steroid Hormone Production. Adipose
tissue contains enzymes that are involved in steroid biosyn-
thesis and is therefore a source of extragonadal oestrogens
in men and women (Figure 3). Adipocytes express 17𝛽-
hydroxysteroid dehydrogenase that converts androstene-
dione to the more active androgen testosterone and converts
oestrone to oestradiol (Figure 4). Aromatase, an enzyme
of the cytochrome P450 family, is encoded by the CYP19
gene [71] and catalyses the final step of oestrogen synthesis
by aromatisation of androgens to oestrogens, in particular
androstenedione to oestrone and testosterone to oestradiol.
Increased adiposity leads therefore to higher local tissue
concentrations of oestrone and oestradiol. There is some evi-
dence that inflammation associated with adiposity increases
aromatase activity [72].
In premenopausal women, aromatase is expressed in
ovarian granulosa cells, placental syncytiotrophoblast cells,
brain, breast cancer, skin fibroblasts, bone osteoblasts, chon-
drocytes, and adipose stromal fibroblasts [73]. Peripheral aro-
matisation is particularly relevant in postmenopausal women
following cessation of androgen and oestrogen synthesis
in the ovaries. In these women, circulating oestrogens are
derived principally by peripheral aromatisation of androgens
produced in the zona reticularis of the adrenal cortex.
A detailed study of the relationship between BMI and
serum oestrogen levels in postmenopausal women showed
an increase in all measures of oestrogen but a most marked
increase in free oestrogen with increasing BMI. Serum
concentrations of themost potent oestrogen, oestradiol, were
twofold higher in the upper quartile compared to in the lower
quartile, 57.9 pM compared to 29.9 pM, and serum oestrone
concentrations were 1.5-fold higher, 133 pM compared to
89 pM.The level of oestrogens increases in obese women due
to the greater amount of adipose tissue and hence aromatase
activity. Obesity causes also a reduction in sex hormone-
binding globulins (Figure 3) and hence there is more free
circulating oestrogen in obese individuals [74]. Free serum
oestradiol was 2.5-fold higher in the upper quartile compared
to in the lower quartile, 29 pM compared to 12 pM.These free
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Figure 4: Continued.
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Figure 4: Steroid hormone biosynthesis and therapeutic prevention of steroid hormone action. The sterol cholesterol which contains 27
carbons and includes four interconnected cyclic hydrocarbons is the precursor of all steroid hormones (a). Removal of the cholesterol
side chain yields the 21-carbon pregnenolone which is metabolised further to give active progestogens which are in turn converted into
glucocorticoids and mineralocorticoids (not shown). Pregnenolone and progesterone may be converted also to 17𝛼-hydroxy pregnenolone
and 17𝛼-hydroxy progesterone which are the precursors of the 19-carbon androgens. Metabolism of androgens by aromatisation of the first
cyclic hydrocarbon and removal of carbon 19 produces the 18-carbon oestrogens. Two important enzymes in the end stages of androgen
and oestrogen synthesis are expressed in adipocytes: 17𝛽-hydrosteroid dehydrogenase converts androstenedione into the much more potent
testosterone and oestrone into themore potent oestradiol. Aromatase converts the androgens androstenedione and testosterone into oestrone
and oestradiol, respectively. All steroid hormones interact with and activate a cognate receptor which is a ligand-dependent transcription
factor. For instance, all active androgens interact with the androgen receptor and all oestrogens interact with an oestrogen receptor. Systemic
therapeutic intervention to inhibit androgen or oestrogen action involves inhibition of enzymes involved in their synthesis (b) or competitive
inhibition of the interaction of the steroid ligands with their receptors (c). Recently, 17𝛼-hydroxylase inhibitors such as abiraterone and
orteronel have been developed and are in clinical trial for the treatment of antiandrogen refractory prostate cancer. Inhibitors of 5𝛼 reductase
such as finasteride and dutasteride are used in the treatment of benign prostatic hyperplasia and male pattern baldness. Aromatase inhibitors
such as type I inhibitor anastrozole and type II steroid inhibitor exemestane are used widely in the treatment of postmenopausal women
with breast cancer. Oestrogen antagonists include the partial antagonist tamoxifen which is a triphenylethylene derivative and the pure
antioestrogen fulvestrant which is a steroid. Androgen antagonists include the nonsteroidal pure antiandrogens flutamide and bicalutamide
which is the mainstay of systemic therapy in prostate cancer patients.
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serum oestradiol concentrations are high enough to occupy
and activate the oestrogen receptor, and because the increase
in oestradiol concentration observed in obesewomen is in the
linear range of response to oestradiol, it would be predicted
to increase significantly the induction of gene expression
and cell proliferation in oestrogen-responsive malignant cells
[75–78]. In breast cancer cells, induction of the expression
of thirteen genes was half-maximal between 20 and 50 pM
oestradiol and the increase in oestradial-stimulated cell
proliferation was half-maximal at 30 pM oestradiol [77, 78].
Local tissue concentrations of oestradiol in obese individ-
uals will exceed most probably those measured in serum
(Figure 3).
3. The Major Molecular Pathways Involved
Several mechanisms have been postulated to explain the
pathophysiology behind the obesity and diabetes-associated
increased risk and progression of cancer. Insulin, IGFs and
their receptors have all been suggested to play an important
role. To understand how these different stimuli might influ-
ence cancer development and progression both individually
and in concert, it is necessary to consider the biochemical
basis of their activity.
3.1. Insulin. As described above, insulin is synthesised in
and then secreted from beta cells of the pancreatic islets
of Langerhans in response to plasma glucose. Insulin was
the first protein to be sequenced and one of the first to
have its structure solved using X-ray crystallography. Insulin
is synthesised as a precursor protein, proinsulin, and is
processed by the removal of a central C peptide which lies
between the B and A polypeptide chains. Insulin comprises
two polypeptide chains: an A chain of 21 amino acid residues
that contains two regions of 𝛼-helix and a B chain of 30
residues that contains a region of 𝛼-helix towards the N-
terminus (Figure 5(a)).The two chains are linked together by
two interchain disulphide bridges.There is a third disulphide
bridge within the A chain between the sixth and eleventh
residues.
3.2. Insulin-Like Growth Factors. The pioneering work of
Salmon Jr. and Daughaday [79] led to the discovery of IGF-1
as the first knownmediator of the effects of growth hormone.
IGF-1 is synthesised by the liver under the control of growth
hormone and stimulates bone growth because it increases
the proliferation of cartilage cells in the epiphyseal plate of
long bones. IGF-1 contains 70 amino acid residues in a single
polypeptide chain and has three intramolecular disulphide
bonds congruent to those found in insulin. It contains the 𝛼-
helix in the same location as that in the B chain of insulin
but the 2 stretches of 𝛼-helix in the equivalent of the A chain
of insulin are less well defined (Figure 5(a)). It retains the
equivalent of the C peptide of insulin and has an additional
sequence, the D domain, at the carboxy-terminus. IGF-2
was discovered at about the same time as IGF-1 [80]. It
is closely related to IGF-1 and is produced primarily by
the liver, but its production is not controlled by growth
hormone. IGF-2 expression is controlled by methylation of
a differentially methylated region located upstream of the
IGF-2 gene. IGF-2 is expressed normally from the paternal
chromosome only as a result of maternal genetic imprinting
[81]. Loss of imprinting leads to overexpression of IGF-2 and
occurs frequently in human cancers [82, 83]. IGF-2 contains
67 residues in a single polypeptide chain, retains a C- and D-
domain, and has a similar structure to those of insulin and
IGF-1 with three congruent intramolecular disulphide bonds.
The boundaries between insulin and IGF signal transduc-
tionwere thought originally to be quite distinct. It has become
apparent that the structural similarities between insulin, IGF-
1, and IGF-2 are sufficiently strong to allow them to interact
with each other’s receptors. Further, their cognate receptors
are closely related and activate many common intracellular
signal transduction molecules.
3.3. The Insulin Receptor. The cellular effects of insulin are
mediated by the insulin receptor. The insulin receptor has a
highest affinity for insulin and a lower affinity for the two
related growth factors, IGF-1 and IGF-2 (Table 3).The insulin
receptor is a cell surface tyrosine kinase receptor of 320 kDa.
The receptor is present in its unbound form in the plasma
membrane as a disulphide-linked heterotetramer which is
referred to usually as the insulin receptor dimer.
After synthesis, the insulin receptor protein under-
goes posttranslational proteolytic cleavage to generate an
amino-terminal 𝛼-chain and a carboxyl-terminal 𝛽-chain
(Figure 6(a)). The two chains are then rejoined covalently
by a disulphide bond between the 𝛼 and 𝛽 chains of each
monomer. The extracellular part of the insulin receptor
dimer, called the ectodomain, contains both 𝛼-chain and 194
residues of each 𝛽-chain. The two monomers in the insulin
receptor dimer are bound covalently by four disulphide
bonds between the two 𝛼 chains.
The crystal structure of the ectodomain of the insulin
receptor dimer has been solved [84, 85], and additional
knowledge is available from molecular modelling, mutage-
nesis of both insulin and the insulin receptor, analysis of
patients with defective insulin signaling, and thermodynamic
and kinetic analyses of the binding reaction [86, 87]. Each
insulin receptor monomer ectodomain comprises a leucine-
rich repeat domain (L1), a cysteine-rich region (CR), and a
second leucine-rich repeat domain (L2) followed by three
fibronectin type III domains: (FnIII-1, FnIII-2, and FnIII-3).
FnIII-2 is interrupted by a ∼120 amino acid residue insert
domain (ID) that contains the furin proteolytic cleavage site
that is cleaved by a protease to create the 𝛼 and 𝛽 chains
(Figure 6(a)). The segments of the ID that are in the 𝛼
and 𝛽 chains are termed ID𝛼 and ID𝛽, respectively. The
single helix that spans the plasma membrane is C-terminal
to the FnIII-3 domain and is followed by the intracellular
domains comprising, a ∼40 amino acid residue intracellular
juxtamembrane region (JM), a tyrosine kinase (TK, dark
International Journal of Endocrinology 13
IGF-1
C domain
B domain
A domain
D domain
N-terminus
C-terminus
IGF-2
C domain
A domain
D domain
C-terminus
B domain
N-terminus
InsulinB chain
A chain
N-terminus
C-terminus
B chain
N-terminus
B chain
C-terminus
A chain
A chain
(a)
IGF-2C-terminus
N-terminus
Surface 1
Surface 2
IGF-1
N-terminus
C-terminus
Surface 1
Surface 2
Insulin
Surface 1
Surface 2
C-terminus
N-terminus
C-terminus
N-terminus
B chain
B chain
A chain
A chain
(b)
Figure 5: Representation of the three-dimensional structures of insulin, IGF-1, and IGF-2, and of the two binding surfaces on the ligands.
Ribbon representations of the three-dimensional structures of the three ligands are shown with the insulin B chain and equivalent B domains
of IGF-1 and IGF-2 coloured in red, the C domains of IGF-1 and IGF-2 in pink, the insulin A chain and A domains of IGF-1 and IGF-2 in
blue, and the D domains of IGF-1 and IGF-2 in green (a). The three insulin 𝛼 helices, one in the B chain and two in the A chain, are visible
as are the equivalent structures in IGF-1 and IGF-2.The positions and orientations of the side chains of the residues implicated in interaction
of the ligands with the receptors are shown on the backbone of the molecule structures which are coloured in grey (b). The side chains are
shown in ball-and-stick view. The side chains of the residues located on binding Surface 1 are coloured in pink and those located on binding
Surface 2 are coloured in blue. Residues ValB12, TyrB16, GlyB23, PheB24, PheB25, TyrB26, GlyA1, IleA2, ValA3, GlnA5, TyrA19, and AsnA21
of insulin are involved in Surface 1 and HisB10, GluB13, LeuB17, SerA12, LeuA13, and GluA17 in Surface 2. For IGF-1, residues Phe23, Tyr24,
Tyr31, Arg36, Arg37, Val44, Tyr60, and Ala62 form Surface 1 and residues Glu9, Asp12, Phe16, Leu54, and Glu58 are thought to contribute to
Surface 2. In IGF-2, residues Val14, Phe28, and Val43 are included in Surface 1 and residues Glu12, Phe19, Leu53, and Glu57 in Surface 2.
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Table 3: Affinities of insulin, IGF-1, and IGF-2 for homodimers and heterodimers of isoform A (IR-A) and isoform B (IR-B) of the insulin
receptor and type I IGF receptor (IGF-IR).
Ligand IR-B : IR-B IR-A : IR-A IR-A : IR-B IGF-IR : IGF-IR IGF-IR : IR-B IGF-IR : IR-A
Insulin 0.5 nM$ 0.25 nM 0.5 nM 100 nM 80 nM 70 nM∗
IGF-1 100 nM 10 nM 40 nM 0.2 nM 0.3 nM 0.4 nM
IGF-2 10 nM 2nM 10 nM 0.5 nM 0.5 nM 0.7 nM
$Affinities are taken from or are estimated from the different relative affinities reported in [92, 100–102, 104, 310]. ∗The affinities reported for the hybrid between
type I IGF receptor and isoform A of the insulin receptor are discrepant.
salmon) catalytic domain, and an ∼100 amino acid residue
carboxyl-terminal tail (C-tail, dull pink).
The structure of the extracellular domains of each recep-
tor monomer resembles an inverted “V” of which the L1-
CR-L2 domains form one arm and the three FnIII domains
form the other. In the receptor dimer, the second monomer
is related to the first by a twofold rotation about the axis of
the inverted “V” which results in the L1-CR-L2 arm of one
monomer being packed against the three FnIII domains of
the other (Figure 7(a)).
3.4. Interaction of Insulin with the Insulin Receptor. Insulin
makes contact with the insulin receptor through two distinct
surfaces. Surface 1 approximates to the surface responsible
for insulin dimerisation, which is known as the “classic
binding surface.” It includes ValB12, TyrB16, GlyB23, PheB24,
PheB25, TyrB26, GlyA1, IleA2, ValA3, GlnA5, TyrA19, and
AsnA21. Surface 2 overlaps the surface on the insulin dimer
responsible for hexamer formation and includes HisB10,
GluB13, LeuB17, SerA12, LeuA13, and GluA17 (Figure 5(b)).
The structure of the insulin : insulin receptor complex
has not been solved. The current model for insulin interac-
tion with the insulin receptor proposes that there are two
equivalent ligand binding pockets in the insulin receptor
dimer. Within each pocket, there are two distinct sites of
interaction with insulin [88, 89]. The central 𝛽-sheet of the
L1 domain from one receptor monomer and the C-terminus
of the FnIII-2 insert domain (𝛼-CT) from the second receptor
monomer constitute one binding site, Site 1 (Figure 7(b)).The
structure of the 𝛼-CT segment has been resolved recently
[84]; residues 693–710 form an 𝛼-helical structure that
is packed against the L1 domain while the remaining 21
carboxy-terminal residues are disordered. Residues at the
junction between FnIII-1 and FnIII-2 domains from the
second receptor monomer constitute the second binding site,
Site 2. High-affinity binding involves interaction of surface 1
of an insulin molecule with Site 1 from mainly one receptor
monomer and surface 2 of the insulin molecule with Site
2 from the second receptor monomer; the insulin molecule
bridges the two receptor monomers. Each ligand binds the
receptor with a stoichiometry of 1 : 1 at physiological concen-
trations. Whilst the receptor dimer has two identical Site 1-
Site 2 binding pockets, insulin molecules cannot occupy both
pockets simultaneously. Interaction of a second ligand with
the previously unoccupied binding pocket accelerates the
dissociation of the first ligand which results in the observed
negative-cooperativity binding mechanism. Relatively little
conformational change in the receptor structure occurs after
high-affinity interaction with ligand [86].
3.5. Isoform A of the Insulin Receptor. Evolution has provided
mammalian insulin receptors with an additional exon, exon
11, which encodes the 12 amino acids from residues 718–729
until just three residues from the carboxyl-terminus (residue
732) of the 𝛼 chain (Figure 6(b)). The extra amino acid
residues are thought to have a disordered structure and are
located just carboxy-terminal to the 𝛼-helical region, which
is packed against the L1 domain to form the insulin binding
Site 1 of the receptor [86]. In mammals, the insulin receptor
can be transcribed without or with exon 11 to produce
isoformA or isoformB, respectively.The discovery of the two
insulin receptor isoforms as part of the original cloning and
sequencing of the insulin receptor mRNA [90] was regarded
initially as a molecular curiosity but is now recognised to be
of considerable relevance to the role of hyperinsulinaemia
and diabetes in cancer risk and cancer progression and in the
potential effectiveness of different IGF-targeted therapies.
The two isoforms have different tissue distributions [91].
Isoform B of the insulin receptor is the predominant form in
classic insulin target tissues such as liver and skeletal muscle
whereas isoformA tends to be expressed in nonclassic insulin
target tissues. Importantly, isoform A is the predominant
form of the insulin receptor expressed in the foetus and in
various types of cancer including breast, colon, lung [92,
93], thyroid [94], prostate [95], and ovary [96]. The ratio of
isoform A to isoform B is higher in breast cancer than in
normal breast tissue [93]. In thyroid cancer, isoform A is
related to differentiation, being expressed at higher levels in
less well-differentiated tumours [94]. Isoform A expression
is not limited to cancers of epithelial origin and is the
predominant isoform in some sarcomas [97] and gestational
trophoblastic neoplasias [98].
3.6. Interaction of Insulin, IGF-1, and IGF-2 with Isoform
A of the Insulin Receptor. Subsequent to the discovery of
isoform A, it was recognised that isoforms A and B had
differing affinities for insulin with isoformAhaving a twofold
higher affinity than isoform B [99]. The absence of exon 11 in
isoform A, however, produces a more promiscuous receptor
with reduced specificity for insulin; isoform A has increased
affinities for IGF-1 and IGF-2. The affinity of isoform A of
the insulin receptor for IGF-1 is about 10-fold higher than
the affinity of the B isoform of the insulin receptor, and for
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Figure 6: Representation of the domain structure of the human insulin and type I IGF receptors.The insulin receptor and type I IGF receptor
are synthesised as single polypeptide chains that comprise several congruent, distinct domains. A linear representation of the domain structure
of the proinsulin receptor isoform B after the removal of the signal peptide is shown above, a representation of the homodimer (a). From the
amino-terminus, the individual domains are coloured as follows: leucine-rich repeat domain 1 (L1, blue), a cysteine-rich region (CR, yellow),
a second leucine-rich repeat domain (L2, blue) followed by three fibronectin type III domains (FnIII-1, FnIII-2, and FnIII-3, different shades
of pale blue). FnIII-2 is interrupted by a ∼120 residue insert domain (ID, grey) that contains the furin proteolytic cleavage site which is cleaved
by a protease to create the 𝛼 and 𝛽 chains of the receptors.The segments of the insert domain that are in the 𝛼 and 𝛽 chains are termed ID𝛼 and
ID𝛽, respectively.The single helix that spans the plasma membrane (TM, dashed line) is C-terminal to the FnIII-3 domain and is followed by
the intracellular domains comprising a ∼40 amino acid residue intracellular juxtamembrane region (JM, dashed line), a tyrosine kinase (TK)
catalytic domain, and an ∼60 amino acid residue carboxyl-terminal tail. Intramonomer and intermonomer disulphide bonds are shown as
ochre coloured connecting lines. The position of the furin cleavage site is indicated below the proinsulin receptor monomer and the position
of the extra 12 amino acid residues present in isoform B of the insulin receptor is indicated below the depiction of the mature insulin receptor
dimer. The amino acid sequences around the furin cleavage sites in isoform A and isoform B [311] of the insulin receptors are shown (b).
The additional 12 residues encoded by exon 11 that are present in isoform B of the insulin receptor are shown in bold. The presence of 12
additional residues, three amino acids from the carboxy-terminus of the 𝛼-chain, in the 𝛼-chain insert domain impinges upon Site 1 of the
insulin receptor binding pocket [84] and affects the ability of IGF-1 and IGF-2 to interact with the insulin receptor isoform B.
IGF-2 it is about 5-fold higher [100, 101].The affinity of IGF-2
for isoform A of the insulin receptor approaches its affinity
for type I IGF receptor (Table 3) [92, 100–102]. Although the
structural basis for the increased affinities of IGF-1 and IGF-
2 for isoform A of the insulin receptor is not understood
completely, it is reasonable to suppose that the removal of the
12 amino acid residues fromwithin the ligand binding pocket
adjacent to binding Site 1 of the insulin receptor provides
space to accommodate the C domain of IGF-1 or IGF-2. The
difference in the relative affinities of the two isoforms for
IGF-1 and IGF-2 may be due to differences between the C-
domains of the two IGFs [103]. The C-domain is smaller in
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IGF-2 than in IGF-1 and may be accommodated more easily
in the binding pocket of isoform B of the insulin receptor
(Figure 5(a)).
3.7. Type I IGF Receptor. Type I IGF receptor and insulin
receptor are thought to have evolved from an ancestral recep-
tor involved probably in the regulation of both metabolism
and growth. The sequences and overall structures of the two
receptors remain very similar to the extent that they can form
functioning heterodimeric hybrid receptors but the ligand
specificity of and the signalling from the two receptors have
diverged considerably. Of the three ligands, IGF-1 has the
highest affinity, IGF-2 a slightly lower affinity and insulin has
amuch lower affinity (∼100 fold) for type I IGF receptor [104]
(Table 3).
As with the insulin receptor, each type I IGF receptor
monomer comprises from the amino-terminus: the first
leucine-rich repeat domain (L1), the cysteine-rich region
(CR), the second leucine-rich repeat domain (L2), the first
fibronectin type III domain (FnIII-1), the second fibronectin
type III domain (FnIII-2), the third fibronectin type III
domain (FnIII-3), the transmembrane domain, the jux-
tamembrane domain, the tyrosine kinase domain, and the C-
terminal tail region. The insert domain of ∼120 residues (ID)
which contains the furin recognition site is within FnIII-2,
and cleavage at this site yields the 𝛼 and 𝛽 chains of type I
IGF receptor monomer.
Whereas the crystal structure of the entire ectodomain of
the insulin receptor has been determined, the crystal struc-
tures of the type I IGF receptor are limited to the L1-CR-L2
domains [105] and intracellular tyrosine kinase domain [106].
Additionally, a solution structure of the ectodomain of the
type I IGF receptormodelled on the insulin receptor structure
has been determined by small-angle X-ray scattering [87].
Overall, the domain dispositions of the ectodomains of the
type I IGF receptor are very similar to those of the insulin
receptor. There are differences between the structures of the
first three domains, L1-CR-L2, that may contribute to ligand
specificity [107]. The first difference is in the structure of the
L1 domain in the second and third 𝛽-strands of the second
leucine-rich repeat. Phe39 in the second (central) 𝛽-sheet
of the insulin receptor is involved in ligand binding and is
a major determinant of the specificity of the receptor for
insulin [108] whereas in type I IGF receptor, the equivalent
residue Ser35 is not involved in ligand binding. The second
difference is in the sixth module of the CR domain which is
thought to govern IGF binding specificity. There are different
amounts of a-helix and numbers of disulphide bonds in, and
little sequence similarity between, the sixth modules of the
two receptors [107]. Compared with the type I IGF receptor,
the insulin receptor has a larger loop that protrudes into the
ligand binding pocket (Figure 7(c)).
3.8. Interaction of IGF-1 and IGF-2 with Their Cognate
Receptor. In contrast to insulin, IGF-1, and IGF-2 exist always
as monomers in solution and have no dimer- or hexamer-
forming surfaces. This difference raised the question of
whether they interact with type I IGF receptor through
two surfaces in a similar way to the interaction of insulin
with the insulin receptor. The overall binding characteristics
are similar to those of insulin. IGF-1 binding exhibits a
curvilinear Scatchard plot indicative of the coexistence of
more than one binding pocket, and binding shows negative
cooperativity [109, 110]. The main difference is that unlike
insulin, there is no loss of accelerated dissociation at high
concentrations of IGF-1.
Identification of the binding surfaces on IGF-1 and
IGF-2 has relied on mutagenesis and cross-linking stud-
ies (Figure 5(b)). Residues equivalent to insulin’s Surface 1
together with residues in the C-domain of IGF-1 that are
important for binding of IGF-1 to Site I of type I IGF receptor
include Phe23, Tyr24, Tyr31, Arg36, Arg37, Val44, Tyr60, and
Ala62 (Figure 5(a)). Alanine scanning mutagenesis has been
useful in defining a second surface which may include Glu9,
Asp12, Phe16, Leu54, and Glu58 and possibly the adjacent
residues Ala8 and Met59 [111]. Thus, the binding of IGF-1
to type I IGF receptor is similar to that of insulin to the
insulin receptor and involves many equivalent amino acids.
Residues critical for the binding of IGF-2 to Site 1 of type I
IGF receptor include Val14, Phe28, and Val43 and the second
surface that engages potentially one or more of the FnIII
domains is formed by Glu12, Phe19, Leu53, and Glu57 [112].
Analysis of the modelled solution structure of the
ectodomain of type I IGF receptor reveals that at saturation
concentrations of IGF-1, threemolecules of the ligand are able
to bind to the receptor. The asymmetry of the interactions
led the authors to suggest that one ligand molecule binds
with high affinity and bridges the two receptor monomers
by interaction simultaneously with Site 1 on a first receptor
monomer and Site 2 on the second receptor monomer. A
further ligand molecule may bind to the available Site 2 on
the first receptor monomer and a third ligand molecule to
Site 1 on the second receptor monomer albeit at around 50-
fold lower affinity. A small conformational change in type I
IGF receptor ectodomain is required to allow it to bind three
IGF-1 molecules simultaneously.
Following interaction of insulin, IGF-1 or IGF-2 with a
receptor and its activation by autophosphorylation, the ligand
receptor complexes are internalised. The activated ligand
receptor complexes continue to signal in the intracellular
vesicles. Eventually, the ligand dissociates within the endo-
somes, the receptors are inactivated by phosphotyrosine-
specific phosphatases and recycled back to the plasma mem-
brane, and the signal is attenuated [113]. As the pathways
have been elucidated, it has become apparent that the same
intracellular proteins transduce the signal from all three
ligands and their different receptors. A major challenge now
is to understand why different responses are manifest in
different cells. The “cellular context” which is the sum of all
the contributions from all the signal transduction molecules
present in the cell is thought to be of great import [114].
3.9. Insulin and Type I IGF Hybrid Receptors. The discovery
that the insulin receptor and type I IGF receptor could form
heterodimeric hybrid receptors revealed an additional level
of complexity [115–117]. Heterodimers form with the same
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Figure 7: Representation of the crystal structure of the ectodomain of the insulin receptor and model for the interaction of insulin and IGF-1
with their cognate receptors. The three-dimensional structures of a monomer (LHS) and homodimer (RHS) of the insulin receptor isoform
B ectodomain are shown (a). Domains are coloured: L1, red; CR, yellow; L2, blue; FnIII-1, green; FnIII-2, cyan; and FnIII-3, magenta. The
observed location of the inter-𝛼-chain disulphide at Cys524 is indicated by a (󳵳) symbol, the 𝛼-𝛽 chain disulphide at Cys647–Cys860 by a (∙)
symbol. Images are taken with permission from [312]. The structures of 𝛼-chain residues 1–3 (𝛼-chain N-terminus) and 656–719 (ID-𝛼/CT)
and of 𝛽-chain residues 724–754 (ID-𝛽) and 910–917 (C-terminus of ectodomain) were not solved. The observed termini of the regions of
resolved structure within the insert domain of the 𝛼-chain and 𝛽-chain of the ectodomain monomer are numbered. The insulin receptor
ectodomain homodimer is illustrated in its apoconformation, with the twofold symmetry axis indicated by a dashed vertical line ((b), LHS)
[85]. The first monomer at the front of the depiction is shown in saturated colour and the second monomer in less intense colour. The thin
tubes of the insert domains (ID) indicate their speculative paths. The circled region identified by a blue arrow represents one binding pocket.
The region contains the juxtaposition of the residues, derived from L1 of the first monomer and the 𝛼CT helix of the second monomer that
contribute to binding Site 1 with the residues, derived from the FnIII-1 and FnIII-2 junction of the second monomer that contribute to Site 2.
The Site 1 tandem element, formed by the surface of the central 𝛽-sheet of L1 of the first insulin receptor monomer and the 𝛼CT helix of the
second insulin receptor monomer, is shown (RHS). Images are taken with permission from [86]. The proposed location of insulin bound in
an insulin receptor binding pocket formed between two insulin receptor monomers with Site 1 from mainly one monomer and Site 2󸀠 from
the second monomer of the insulin receptor ectodomain [85, 107, 312] is shown in (c) (LHS). Domains of the receptor are coloured as in (a).
Colouring of individual C𝛼 positions within insulin is as follows: residues forming binding Surface 1 of insulin, A1–3, A5, A19, A21, B12, and
B16, are shown in purple; residues forming binding Surface 2, A12-13, A17, B13, B17, and B19, are shown in orange; the remaining A-chain
residues are in light green and remaining B-chain residues in light blue. Insulin residues B22–B30 are omitted from the model [107]. The
proposed location of IGF-1 bound at Site 1 of type I IGF receptor binding pocket is shown (RHS) [313]. The colouring of domains of the type
I IGF receptor follows that of the insulin receptor in (a). The backbone of IGF-1 is coloured according to the corresponding colours of the A
and B chains of insulin outlined above. The images are taken with permission from [312].
efficiency as homodimers which means that the number of
hybrid receptors is determined by the level of expression of
each receptor and that if one receptor is present in excess of
the other, there will be relatively few homodimers of the other
receptor [118].
Early studies showed that the hybrid receptors have
unusual binding properties; IGF-1 is displaced by low con-
centrations of IGF-1 but can only be displaced by high
concentrations of insulin. In comparison, insulin is displaced
by low concentrations of both insulin and IGF-1, with IGF-1
being more effective.These results suggest that IGF-1 inhibits
allosterically insulin binding via interaction with type I IGF
receptor monomer 𝛼-subunit in the hybrid receptor [117].
More recent analysis of the relative binding affinities
and signalling capabilities of receptor heterodimers formed
between either of the two insulin receptor isoforms and type I
IGF receptor indicate that both hybrid receptors have a lower
affinity for insulin than for either IGF-1 or IGF-2 (Table 3)
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[101, 119]. It has been suggested that the heterodimer between
isoform A of the insulin receptor and type I IGF receptor
may be considered as a relatively low specificity receptor with
which IGF-1 and IGF-2 interact with high affinity to activate
signal transduction. Although insulin has a lower affinity
than the IGFs for this hybrid receptor, it could be activated
by the high insulin concentrations present in insulin-resistant
individuals with hyperinsulinemia in whom serum insulin
concentrations can be as high as 0.8 nM [120, 121]. The
high concentrations of therapeutic insulin required to reduce
postprandial blood glucose in patients with diabetes mellitus
type II reach 0.5 nM which is sufficiently high also to occupy
this hybrid receptor [122].
3.10. Type II IGF Receptor and Insulin-Like Growth Factor
Binding Proteins. Type II IGF receptor is located in the
plasma membrane and interacts with IGF-1 and IGF-2. Type
II IGF receptor has a higher affinity for IGF-2 than IGF-1
and does not bind insulin. It is also a receptor for mannose 6
phosphate forwhich it containsmultiple interaction domains.
Type II receptor does not transduce a signal but effectively
lowers the bioavailability of IGF-1 and IGF-2 because after
interaction, the ligand and receptor are internalised and
degraded.
IGF-1 and IGF-2 are bound to insulin-like growth factor
binding proteins (IGFBPs) in the circulation [123]. IGFBP3
is the major IGFBP with which IGF-1 and IGF-2 are com-
plexed in the serum. IGFBPs protect IGF-1 and IGF-2 from
degradationwhilst in the circulation and deliver them to cells.
The IGFBPs help to control the action of IGF-1 and IGF-2
by increasing their half-lives. The half-life can be increased
from tenminutes to 15 hourswhen bound to IGFBPs. Because
IGFs have a higher affinity for IGFBPs than for type I IGF
receptor, the IGFBPs decrease the activation of the receptors
and modulate the IGF response [124, 125].
4. Biological Effects and Consequences
4.1. Metabolic Effects of Insulin. Interaction of insulin with
the insulin receptor initiates the recruitment of intracellular
signal transduction molecules and culminates in the acti-
vation of metabolic pathways. Activation of the receptor
causes tyrosine autophosphorylation on Tyr1146, Tyr1150,
and Tyr1151 [126]. The receptor tyrosine kinase is now fully
active and phosphorylation of juxtamembrane and carboxyl-
terminal residues that form binding sites for docking proteins
ensues. The sequence context of the phosphorylated residues
determines which protein interaction domains are able to
bind to the phosphorylated receptor and dictates thereby
the docking proteins that are recruited and activated [127].
These adaptor molecules are in turn phosphorylated by the
active receptor kinase. Effector proteins interact with phos-
phorylated adaptor proteins via different protein interaction
domains such as SH3 and PDZ domains and the signal
transduction cascade is initiated.
In man, the adaptor proteins are the insulin receptor
substrates, IRS-1, IRS-2, and IRS-4, and Shc. The adaptor
proteins have no intrinsic catalytic activity but transmit
signal from the activated receptor to effector proteins. For
example, IRS-1 interacts with the activated insulin receptor
via a phosphotyrosine binding domain and with the inner
side of the plasma membrane via its pleckstrin homology
domain. IRS-1 is then phosphorylated on multiple tyro-
sine, serine, and threonine residues including two tyrosine
residues within YXXMmotifs, Tyr612 and Tyr632. Activation
of phosphatidylinositol-3 kinase (PI-3 kinase) requires inter-
action of both its SH2 domains with these phosphorylated
motifs [128].
PI-3 kinase activation leads to phosphorylation of the
protein kinase Akt onThr308. Full activation of Akt requires
a second phosphorylation on Ser473. Phosphorylation of
Akt and hence its substrates is a key event in transmission
of the insulin signal. Uptake of glucose into tissues that
express GLUT4 glucose transporters, such as skeletal muscle
and liver, is stimulated immediately after insulin is released
into the blood stream. Insulin increases glucose transporter
GLUT4 numbers at the cell surface by recruitment from
an intracellular pool because activated Akt phosphorylates
AS160 and TBC1D1 which are then phosphorylated by addi-
tional kinases. Phosphorylated AS160 and TBC1D1 activate
small GTPases of the Rab family which are important in
vesicle trafficking. GTP loading of Rab-GTPases in GLUT4-
positive intracellular vesicles increases interaction with Rab
effectors that control GLUT4-positive vesicle transport to the
plasma membrane and hence uptake of glucose from the
plasma (Figure 8).
Akt phosphorylates also glycogen synthase kinase 3
(GSK-3). GSK-3 is active only in its unphosphorylated form
and is thereby inactivated. Its substrate, glycogen synthase
is inactivated also by phosphorylation and therefore the
inactivation of GSK-3 results in an increase in active, unphos-
phorylated glycogen synthase. This active glycogen synthase
converts glucose into glycogen, the high-molecular-weight
polymeric storage form of glucose. As well as generating
a major energy source, conversion of glucose to a high-
molecular-weight polymer solves elegantly the osmotic prob-
lems associated with high concentrations of a low-molecular-
weight solute which are a major cause of tissue damage in
diabetics (Figure 8).
Activated docking proteins stimulate also the transcrip-
tion of insulin-regulated genes. For instance, the nucleotide
exchange factor growth factor receptor-bound protein 2
(Grb2) binds the phosphorylated Tyr896 motif of IRS-1
via its SH2 domain [129]. Grb2 is then able to bind the
guanine nucleotide exchange factor, son of sevenless (SOS),
which in turn catalyses the replacement of bound GDP
with GTP on the Ras GTPase. This protein phosphorylation
cascade culminates in activation ofmitogen-activated protein
kinases (MAPKs), which enter the nucleus and phosphory-
late nuclear transcription factors. Effects of insulin on gly-
colysis are mediated by increased expression of hexokinase,
phosphofructokinase, and pyruvate kinase, the enzymes that
control the three irreversible steps of glycolysis (Figure 8).
Insulin can stimulate nonmetabolic effects via interaction
with the insulin receptor and activation of the MAPK
pathway [130]. This role of insulin may be more significant
in cancer cell biology than recognised previously. There is
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Figure 8: Graphic representation of the classic modes of insulin, IGF-1, and IGF-2 signal transduction. Insulin binds to the ectodomain of the
insulin receptor and activates both the PI3-kinase and Akt pathway (blue) and the Ras andMAP kinase pathway (salmon pink). Activation of
the Akt pathway results in translocation of GLUT4-positive intracellular vesicles to the plasma membrane and increased uptake of glucose,
activation of glycogen synthase kinase 3 and the conversion of glucose to glycogen, and activation of pyruvate dehydrogenase and acetyl-
CoA carboxylase and the conversion of glucose into the substrate for fatty acid synthesis. Activation of the MAP kinase pathway leads to
increased expression of enzymes in the glycolytic pathway and preferential metabolism of glucose for energy. IGF-1 or IGF-2 (IGFs) bind to
the ectodomain of type I IGF receptor and activate both the PI3-kinase andAkt pathway (blue) and the Ras andMAP kinase pathway (salmon
pink). Activation of the Akt pathway results in inhibition of the Bcl-2 family of stress detection proteins and activation of GSK3𝛽, both of
which increase cell survival. Activation of the MAP kinase pathway leads to increased expression of genes that encode proteins important in
regulation of cell cycle progression and hence to increased proliferation.
evidence that the mitogenic response to insulin is more
pronounced after activation of isoform A of the insulin
receptor, which is overexpressed in some tumour cells, than
after activation of isoform B of the receptor [104]. In cancer
patients with insulin resistance, the consequent high levels
of circulating insulin, together with overexpression of the
insulin receptor by the tumour cells, stimulate significant
nonmetabolic effects [100].
4.2. Biological Actions of IGF-1 and IGF-2. As for the insulin
receptor, activation of type I IGF receptor occurs after ligand
interaction in the extracellular domain. This interaction
induces small conformational changes which lead to an
increase in the intrinsic kinase activity of the receptor and
autophosphorylation of Tyr1131, Tyr1135, andTyr1136 residues
in the kinase domain [131].
The classic function of both IGF-1 and IGF-2 is to
stimulate growth. The major signal transduction pathways
responsible is thought to be the Ras and MAPK pathway
(Figure 8). After phosphorylation of IRSs or Shc, the Grb2
protein is recruited via its SH2 domain. Grb2 and SOS are
then able to interact via an SH3 domain which brings SOS in
close proximity to the membrane anchored Ras and reverses
its autoinhibition. SOS promotes dissociation of GDP from
Ras which allows GTP to bind, and after dissociation from
SOS, active GTP-bound Ras phosphorylates its substrate Raf
and the signal cascade is committed. Ultimately, the MAP
kinase enters the nucleus to alter the expression of its target
genes, and cells are driven through the cell cycle.
Activation of the protein kinase Akt by phosphoryla-
tion via the same pathway as described above for insulin
is considered important in the prosurvival effect of IGFs
(Figure 8). Activated Akt promotes cell survival via multiple
effectors. One important pathway involves the Bcl-2 family of
proteins. Akt phosphorylates BAD a proapoptotic member of
the “stress detecting” Bcl-2 family of proteins. BAD induces
apoptosis by interaction with and inhibition of the antiapop-
totic Bcl-2 familymembers Bcl-xL and Bcl-2, which displaces
them from interactionwith proapoptotic proteins such as Bak
and Bax.The liberated Bak and Bax are then able to aggregate
and increase the porosity of mitochondria.Themitochondria
release cytochrome c which activates caspases and induces
caspase-dependent cell death. Because phosphorylated BAD
does not form heterodimers with Bcl-xL or Bcl-2, phospho-
rylation of BAD by Akt inactivates BAD and allows proteins
like Bcl-2 to inhibit proapoptotic proteins. Akt activates also
by phosphorylation GSK3𝛽. GSK3𝛽-dependent cell survival
implicates nuclear factor-𝜅B activation [132] and negative
regulation of both intrinsic and extrinsic caspase-dependent
proapoptotic pathways [133].
IGFs may also be involved in angiogenesis through
induction of HIF-1𝛼 and VEGF-C and by direct actions on
vascular and lymphatic endothelial cells [134–139].The effects
of IGFs on invasion and metastasis include disruption of
𝛽-catenin and E-cadherin complexes which promotes cell
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detachment. IGFs promote invasion by regulating the expres-
sion of matrix metalloproteinases (MMPs) and urokinase
plasminogen activator receptor system, both of which are
involved in degradation of the extracellular matrix (ECM) in
cancer [140, 141].
4.3. Differential Insulin, IGF-1, and IGF-2 Signal Transduction
from Isoform A of the Insulin Receptor. There is evidence for
subtle differences in insulin and IGF-2 signal transduction
via isoform A compared to via isoform B of the insulin
receptor; insulin stimulates mainly glucose uptake and IGF-2
stimulates preferentially proliferation [142]. Signals through
the A isoform may recruit a different repertoire of proteins
from signals through to the B isoform [143] and may deliver
mitogenic signals in addition to metabolic signals [144–146].
Although the molecular basis of the differences in signal
transduction is not understood completely, it may result from
either or both of two properties: the residency time of the
ligand on the insulin receptor and the ratio of affinities for
the insulin and type I IGF receptors. Glu12 in IGF-2 and
its equivalent Glu9 in IGF-1 are located on binding Surface
2 of the ligands and are important for high-affinity binding
to the A isoform of the insulin receptor and type I IGF
receptor. Introduction of a positive charge at this location in
IGF-2 reduces affinity for both receptors and introduction
of a positive charge at the equivalent position in IGF-1,
Glu9Lys, reduces affinity for type I IGF receptor [147]. In
insulin, the equivalent residue is HisB10 and substitution
with an aspartic acid or glutamic acid acidic residue creates
an analogue with a reduced “off-rate” from the insulin
receptor and increased affinity for and activation of type
I IGF receptor. This analogue has increased mitogenicity
and increases mammary tumourigenesis in rats, supporting
the contention that the kinetics of interaction of a ligand
with each receptor contribute to the final biological effect
stimulated by the interaction [148, 149].
4.4. Role of Insulin, IGF-1, and IGF-2 in Cancer. There is
little evidence for the dramatic overexpression or mutation of
components of the insulin and IGF signal transduction path-
ways in malignant cells, or for corruption by transforming-
viruses, that led to the identification of other oncogenes such
as epidermal growth factor receptor or ErbB-2.The absence of
oncogenic evidence for the importance of the IGF system in
cancer delayed the realisation of its import [150–154].There is
however compelling evidence, included from animal models
of tumour formation and progression, for the importance in
IGFs in carcinogenesis. The question in the context of the
present review is the extent to which the insulin and IGF
signal transduction system is responsible for the effects of
obesity and diabetes on cancer risk and progression.
4.5. Insulin and the Insulin Receptor Isoforms and Cancer Risk.
Thepossibility that the hyperinsulinaemia in individuals who
develop metabolic syndrome predisposes towards cancer
implicates a direct effect of high plasma insulin concentra-
tions. There is evidence that plasma levels of insulin or the
C-peptide, which is the peptide that is cleaved from insulin
during its biosynthesis, are associated with colon [155–
158], endometrial [159], breast [158, 160], prostate [161] and
pancreatic [162] cancers. Similarly, the hyperinsulinaemia
that occurs during treatments for diabetes could be causative.
Epidemiological studies of cancer risk in diabetic patients
treated with the biguanide, metformin provide support for
the importance of hyperinsulinaemia in diabetes-associated
cancer risk. Diabetic patients who do not take metformin
to control their diabetes have a 40% higher cancer burden
compared to diabetic patients who do [23, 163]. Metformin
reduces the levels of circulating insulin and decreases the
levels of glucose in the blood; it is probably through these
effects that metformin decreases cancer risk.
In 1990, it was found that insulin receptors are often
expressed at higher levels on tumour cells than on classic
insulin target cells [164]. This high expression was unex-
pected as the majority of cancers do not derive from the
principle target organs of insulin, and cancer cells have
highly effective insulin-independent glucose uptake mecha-
nisms [165]. It is now recognised that the insulin receptor
is expressed by many malignant tumours [100] including
those of prostate [95], lung [166], thyroid, colon [92], and
breast [164]. Studies have identified transcription factors
and cofactors that regulate expression of insulin receptor in
tumour cells [167–169].
The isoformof the insulin receptor presentmay be impor-
tant in the development of cancer.Themajor insulin receptor
isoform expressed on cancer cells is the A isoform which
has a higher affinity for insulin than the B isoform and is
more readily activated by circulating insulin. Isoform A may
also provide a more mitogenic stimulus than the B isoform
which would be associated with a higher cancer risk [170].
Another mechanism by which insulin could increase the
risk of cancer in obese individuals with hyperinsulinaemia
is by direct stimulation of type I IGF receptor. Although
the affinity of insulin for type I IGF receptor is low, the
supraphysiological concentrations of insulin present in obese
people with insulin resistance and hyperinsulinaemia and in
those with the metabolic syndrome are probably sufficiently
high to signal through this receptor. Serum concentrations
of insulin can reach 0.8 nM, at which concentration insulin
would occupy and activate type I IGF receptor [120, 121]
(Table 3).
The hyperinsulinaemia that occurs in obesity may
increase cancer risk by indirect mechanisms. Hyperinsuli-
naemia lowers the plasma concentrations of IGFBP-1 and
IGFBP-3 [171, 172] which increases free circulating IGF-
1. Chronic hyperglycaemia decreases IGFBP-2 to increase
bioactive IGF levels [173]. High insulin concentrations in
the hepatic portal circulation increase growth hormone
receptor expression, thereby augmenting IGF-1 production
[174]. In essence, obese individuals with hyperinsulinaemia
and hyperglycemia will have higher concentrations of free
circulating IGF-1 and augmented activation of the IGF-
dependent proliferation pathway.
Therapeutic insulin has been shown to increase cancer
risk in numerous studies. Further, it has been shown that
the duration of insulin treatment is associated positively with
cancer incidence [175]. More recent studies have investigated
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if treatmentwith insulin analogues is associatedwith a similar
or greater risk than treatment with unmodified insulin.
Treatment of diabetes mellitus type 2 patients with the long-
acting insulin analogue, glargine, was found to be associated
with an increased incidence of all cancers compared to
natural therapeutic insulin in two studies [176, 177] and
in pancreatic and colorectal cancer in a third study [178]
whereas in a fourth study the increased risk for breast cancer
was equal to unmodified insulin [179]. These conclusions
were controversial and provoked extensive debate because of
the implications for diabetics and pharmaceutical companies
[149]. Reservations about the methodology and comparison
groups have been expressed and larger studies are underway.
One recent study confirmed an increased risk of breast cancer
for patients given glargine, comparedwith those givennatural
insulin [180].
4.6. Insulin and the Insulin Receptor Isoforms and Cancer
Progression. There has been a steady increase in the interest
in the importance of insulin and the insulin receptor in cancer
progression. High fasting insulin levels are associated with
higher risk of colorectal adenoma recurrence [181] and with
a poor breast cancer prognosis [182]. High serum insulin
C-peptide levels are associated with a worse prognosis in
prostate [26] and breast cancers [183]. More rapid tumour
progression is associated with hyperinsulinaemia, and the
dependence has been confirmed in animal models [184].
The type of insulin receptor isoform present in malignant
cells may play a role in the progression of cancer as well as
in cancer risk. Studies on breast cancer have shown that the
ratio of isoform A to isoform B is important in determining
the nature of the cancer [185]. Women with an increased
ratio of isoform A to isoform B have more aggressive and
rapidly progressive breast cancer [186]. The ability of the
insulin receptor to form hybrids with type I IGF receptormay
contribute to the effects of insulin on cancer progression. In
essence, the impact of insulin on cancer risk may be large
because of its capacity to deliver a more mitogenic, IGF-like
signal either through isoform A of the insulin receptor or
through insulin receptor: type I IGF receptor hybrids.
4.7. IGFs and Cancer Risk. Meta-analyses and recent large
studies on the relationship between height and cancer risk
have shown that height is a risk factor for some common can-
cers. The most consistent and convincing associations are for
colorectal, breast, and prostate cancers [187]. Interpretation
of the epidemiological data is that increased height reflects
higher circulating levels of the growth stimulatory hormones
particularly the IGFs during prepubertal development. The
length of the long bones in the legs is a major contributor
to adult height and is dependant largely on exposure to IGFs
which is partly determined by genetics and partly by prenatal
and childhood nutrition [188].
More direct evidence for a role for IGFs in the develop-
ment of cancer was provided in 1998 when Hankinson et al.
reported that the risk of breast cancer was associated with
the levels of circulating IGF-1 and IGFBP-3 [189]. Notably,
there was a large increased relative risk of 7.3 for developing
breast cancer in premenopausal women who were in the
top tertile for high serum IGF-1 concentrations and had low
circulating IGFBP3 concentrations. A high ratio of IGF-1
to IGFBP3 means that more IGF-1 is bioavailable. Similar
findings were reported for prostate cancer risk [190] with a
2.4-fold higher risk for men in the highest quartile of IGF-1
concentration compared to men in the lowest. The following
year, an association was reported for colorectal cancer [191].
In 1999, a small increased risk of lung cancer was reported in
people with elevated serum IGF-1 [192].
Thus, by the turn of the century, the prevailing view
corroborated by clear evidence was that there is increased
risk of common cancers in people with elevated circulating
IGFs and low circulating IGFBPs, which supports earlier
conclusions based on the association between height and
cancer risk [193].
4.8. IGFs and Cancer Progression. Normal levels of circu-
lating IGFs are sufficient to stimulate type I IGF receptor
but tumour stroma and malignant cells can produce higher
intratumour concentrations of IGFs. There are few reports
of autocrine IGF-1 production but reports of autocrine IGF-
2 production are common. IGF-1 is expressed in colon
carcinoma [194, 195] and IGF-2 is expressed in breast [196,
197], prostate [198], colorectal [199], adrenocortical [200]
liver [201, 202], and thyroid [94] carcinoma cells and several
types of sarcoma including osteosarcomas, myosarcomas,
fibrosarcomas, and Ewing’s sarcoma [203, 204]. Such high
intratumour IGF concentrations enable heightened IGF sig-
nal transduction and consequent cancer cell proliferation,
survival, and invasion.
Most studies on cancer progression have focussed on type
I IGF receptor and the intracellular IGF signal transduction
pathway. Type I IGF receptor and components of the IGF
signal transduction pathways are expressed by most tumour
types [152, 154, 205–207]. In some cancers, increased type
I IGF receptor expression is associated with worse disease
prognosis. In colorectal cancer, there is a stepwise increase in
the expression of type I IGF receptor during progression from
colonic adenomas towards primary colorectal adenocarcino-
mas andmetastases [208]. For breast cancer, one study found
that higher levels of type I IGF receptor were correlated with
a worse prognosis for all tumours and in oestrogen receptor-
negative tumours [209] whereas another [210] found no
prognostic value. In prostate cancer, there is a significant
increase in type I IGF receptormRNA and protein expression
in primary tumours and in bone metastases, compared to
benign prostatic epithelium [211, 212]. Similar associations
have been reported for less common cancers including
synovial sarcoma [213],melanoma [214], and gastric [215] and
renal clear cell carcinomas [216]. Some studies have shown
that high levels of receptor or phosphorylated receptor are
associated with a poor prognosis [166, 217].
IGFs help metastatic cells adapt to a new environment
although the mechanisms are not well defined. IGF-1 facil-
itates the establishment of both lung [218] and colon [219]
cancer metastases in the liver. IGFs may be involved also in
metastasis of prostate cancer to bone. Osteoblasts and bone
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endothelial cells produce IGFs and IGFBPs [220, 221] whilst
prostate cancer cells produce uPA [222] which degrades
IGFBPs and hence increases the bioavailability of IGFs [223].
4.9. Cooperation between Obesity-Associated Factors in Can-
cer Risk. Obesity aggregates several risk factors, some of
which are particularly relevant to certain types of cancer.
For example, hyperinsulinaemia, diabetes, and serum IGF
levels are all independent risk factors for breast and colon
cancers and may account for the increased risk associated
with obesity. Hyperinsulinaemia and diabetes are associated
with endometrial cancer. The associations identified may
reflect the scope of the different epidemiological studies or
they may reflect divergent cancer cell biology. There are
clear interactions between obesity, insulin, and IGFs which
compound their effects on cancer risk. In addition, steroid
hormones regulate the expression of components of the IGF
signal transduction pathway in some cancer cells and as a
consequence can increase the cancer risk associated with
hyperinsulinaemia, diabetes, and high serum IGF levels.
Hyperinsulinaemia stimulates androgen synthesis in the
ovary, increases aromatisation of androgens to oestrogens,
and decreases hepatic production of sex hormone-binding
globulin which leads to increased bioavailable androgens
and oestrogens [224, 225]. As circulating concentrations of
insulin and IGF-1 rise with increasing obesity, the levels
of the sex hormone-binding globulins decrease [226]. For
instance, a woman with a BMI of >30 kg/m2 has half as
much sex hormone-binding globulin as a woman with a BMI
of <22 kg/m2 [227]. In normal or premalignant cells, the
higher concentrations of, for example, bioavailable oestro-
gens present in obese women could augment the proliferative
and anti-apoptotic effects of insulin and the IGFs with
potentially oncogenic consequences.
There is some evidence that insulin resistance and high
levels of IGFs, which are associated with central obesity, may
play a more important role in premenopausal breast cancer
while oestrogen may play a greater role in postmenopausal
breast cancer [189, 228]. Furthermore, obesity influences the
type of tumour that arises. For example, basal-like or triple-
negative breast tumours which do not express oestrogen
and progesterone receptors or HER2 are more prevalent
in obese women [229, 230]. Interestingly, cell proliferation
and survival of triple-negative breast cancer cells is IGF
dependent [231].
4.10. Cooperation between Obesity-Associated Factors in Can-
cer Progression. The interaction between steroid hormones
and the IGF signal transduction pathway plays an important
role in cancer progression and has been studied mainly in
breast cancer. The significance of oestrogens in progression
in vivo was demonstrated by Beatson [232] but it was not
clear if there was a direct effect on breast epithelial cells.
This question was resolved when cultured malignant breast
cells were shown to contain oestrogen receptors [233] and
their proliferation was shown to be oestrogen responsive
[234, 235]. It became apparent subsequently that oestro-
gens control proliferation by modulating the effect of IGFs
rather than by regulating the expression of genes involved
in the cell cycle. The synergistic effects of oestrogens and
IGFs on proliferation [78, 236] suggested that oestrogens
might control the expression of components of the IGF
signal transduction pathway.There is evidence that oestrogen
increases expression of IGF-2 [237] but there is most likely
an adequate supply of IGFs from the circulation and the
stroma in vivo and in tissue culture medium in vitro. The
main way that oestrogens potentiate the response of breast
cancer cells to IGFs is probably by induction of the expression
of components of the IGF signal transduction pathway [238]
including type I IGF receptor [78, 239], IRS-1 [240–242], and
IRS-2 [243].Oestrogensmay also regulate IGF-stimulated cell
migration via increased IRS-1 and IRS-2 expressions as these
are both involved in breast cancer cell migration [243].
Despite the association between IGFs and cancer pro-
gression and the androgen responsiveness of prostate cancer,
there is little evidence of interaction between androgens and
IGFs in an analogous way to oestrogens and IGFs in breast
cancer. Androgens increase type I IGF receptor expression in
prostate cancer cells [244] but few studies have investigated if
androgens and the IGF signal transduction system interact to
stimulate prostate cancer cell growth.
5. Treatment Targeted to
Adiposity-Induced Cancers
Cancers that have arisen in obese or diabetic individuals
will have identifiable properties that will allow them to be
treated with specific therapies. These properties will reflect
the forces that drove their origin and progression. We have
presented evidence in this review that cancers that arise in a
background of obesity and diabetes are dependent on insulin,
IGFs, and their interactions with steroid hormones. Breast
cancer is treated commonly with oestrogen-based endocrine
therapies. More recently, the appreciation that some cancers
are responsive to IGFs has led to the development of drugs
that target the IGF signal transduction pathway and in some
instances the insulin signal transduction pathway.
Strategies for targeting the IGF signal transduction sys-
tem include antibodies to the cell surface receptors, tyrosine
kinase inhibitors, siRNA [245], dominant negative constructs
[246, 247], antibodies to the ligands [235], and IGF binding
proteins.
5.1. Antibodies to Type I IGF Receptor. The component of the
IGF signal pathway against which most potential drugs have
been developed is type I IGF receptor. A number of human-
ised monoclonal antibodies specific for type I IGF receptor
have been produced including figitumumab, cixutumumab,
ganitumab, dalotuzumab, AVE1642, and R1507 [248–253].
They are of different subclasses but are generally long lasting
with a half-life of greater than 10 days. After interaction
with the ectodomain of the receptor, they promote receptor
internalisation and lysosome-mediated receptor degradation.
Although the antibodies do not recognise directly insulin
receptors, they can bind to and inhibit the activity of hybrid
receptors that are formedwith either theA or B isoformof the
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Figure 9: Therapeutic strategies to inhibit insulin, IGF-1, and IGF-2 signal transduction. Graphic representations of the insulin receptor
isoform B (IR-B, dark blue), the insulin receptor isoform A (IR-A, lighter blue), and of the type I IGF receptor (IGF-IR, pink) are shown
as homodimeric or heterodimeric hybrid receptors. For each receptor monomer, the 𝛼-chain is coloured slightly lighter than the 𝛽-chain.
Bars indicate the approximate positions of the single disulphide bonds between the C647 in the 𝛼-chain and C860 in the 𝛽-chain of each
receptor monomer (yellow); the single disulphide bond between the FnIII-1 domains of each of the two 𝛼 chains in each dimer is obscured.
The extracellular ligands, insulin (orange), IGF-2 (ochre), and IGF-1 (pale yellow), are shown as triangles.The downward pointing grey arrows
indicate that a signal has been transduced from a receptor dimer (a). The deep yellow spheres attached to the ectodomains of the activated
receptors represent phosphorylated residues. Antibodies against IGF-1 and IGF-2 (IGF mAb; yellow), and recombinant insulin-like binding
protein as an incomplete sphere (rIGFBP; light blue), are shown. Inhibition of a signal transduction molecule that is affected by one of the
inhibitors is indicated by an inhibition symbol (brick red). Absence of a signal from a receptor dimer is indicated by a red cross below the
receptor dimer (b). Monoclonal antibodies against IGF-1 and IGF-2 will not inhibit insulin signal transduction. Recombinant IGFBP will
inhibit IGF-1 and IGF-2 but will not inhibit insulin. Antibodies specific for type I IGF receptor are shown (Type I IGF receptor mAb; deep
pink) (c). Antibodies specific for the type I IGF receptor will inhibit type I IGF receptor homodimer and its hybrid receptors formed with
both isoforms of the insulin receptor but will not inhibit insulin receptor homodimers or hybrids of the two isoforms of the insulin receptor.
Representations of tyrosine kinase inhibitors (TKIs) that inhibit both the insulin and type I IGF receptors (tyrosine kinase inhibitor; violet)
are illustrated (d). Tyrosine kinase inhibitors that affect type I IGF receptor and the insulin receptor will inhibit signal transduction via all
the insulin and IGF signal transduction pathways. Tyrosine kinase inhibitors that are specific for the type I IGF receptor will inhibit the type
I IGF receptor homodimer and its hybrid receptors but will not inhibit insulin receptor homodimers or hybrids of the two isoforms.
insulin receptor (Figure 9) [153, 254]. The antibodies should
have therefore activity in cells that express insulin receptors
as long as type I IGF receptor is in excess.
Type I IGF receptor targeted antibodies have some
undesirable side effects, notably hyperglycaemia. Blockade
of type I IGF receptor in the hypothalamic pituitary axis is
interpreted as a fall in circulating IGF-1 and as a consequence,
growth hormone secretion is elevated. The net effect is a
twofold increase in serum growth hormone concentrations,
a modest increase in fasting glucose (<20%) and an elevation
in fasting insulin [248]. The induction of hyperglycaemia is
thought to result from peripheral insulin-resistance associ-
ated with elevated levels of growth hormone. This side effect
has resulted in the inclusion of growth hormone antagonists
and glucose-lowering agents in some clinical trials.
There are upwards of 50 ongoing clinical trials of type
I IGF receptor antibodies in combination with other treat-
ments such as radiotherapy, chemotherapy, or inhibitors
of other signal transduction pathways. Trials of receptor
antibodies in combination with irradiation and chemother-
apeutic drugs are based on the observations that type I
IGF receptor causes radio- and chemoresistance in cell
culture [255, 256] and in xenograft models by reducing
apoptosis and increasing DNA replication and the repair of
double-stranded breaks [257–261]. Trials have yielded mixed
results with some being abandoned because of the frequency
of adverse events or the low probability of achieving the
endpoint of increased survival. Responses to single-agent
therapy have been observed in sarcomas and adrenocortical
carcinoma; prolonged periods of stable disease have been
reported [251, 253, 262, 263]. Some regard these results as
disappointing but others regard them as encouraging because
the trials have been on unselected, heavily pretreated patients
[264].
5.2. Small Molecule Inhibitors of Tyrosine Kinase Activity. The
majority of the small molecule inhibitors that have been
developed compete with ATP to bind to the catalytic tyrosine
kinase domain of type I IGF receptor and hence inhibit
its enzymatic activity: linisitinib, BMS-754807, and INSM-
18 [265, 266]. An exception is the picropodophyllin, AXL-
1717, which is a non-ATP competitive inhibitor of the receptor
kinase. The small molecule inhibitors are characterised by
a short half-life which allows for easier control of their
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activity but requires frequent administration. They have the
advantage compared with the therapeutic antibodies that
they may be administered orally and may cross the blood
brain barrier. They are generally less specific for type I IGF
receptor than the antibodies, but have varying degrees of
specificity for type I IGF receptor (Figure 9). For example,
AXL-1717 is highly selective for type I IGF receptor whereas
linisitinib inhibits the tyrosine kinases of both the insulin
and type I IGF receptors. BMS-754807, is predominantly a
dual type I IGF receptor and insulin receptor inhibitor which
inhibitsMET,TRKA,TRKB,AuroraA, andAurora B kinases
at high concentrations and INSM-18 inhibits type I IGF and
insulin receptors and ErbB2 [254, 267].
Clinical trials of the tyrosine kinase inhibitors are not as
advanced as trials of the inhibitory antibodies.The former are
well tolerated and have shown antitumour activity in phase
I dose escalation trials. They are being evaluated currently
as single agents for the treatment of cancers in which the
early trials showed evidence of a response, or in combination
with cytotoxic drugs or inhibitors of other signal transduction
pathways [264, 265].
5.3. Alternative Targeting Strategies. Therapeutic antibodies
to the IGFs, and recombinant IGF binding proteins, are
being developed to inhibit the effects of IGFs. MEDI-573 is
a humanised monoclonal antibody that interacts with both
IGF-1 and IGF-2. MEDI-573 prevents the IGFs binding to
type I IGF and insulin receptors without affecting glucose
homeostasis [268]. Cell growth of implanted malignant
prostate cells is arrested in an animal model [269] and
MEDI-573 has stabilised disease progression in phase I trials
[254]. Recombinant IGFBP3 has been shown to lower the
bioavailability of IGFs and to reduce tumour growth rate in
animal models of trastuzumab-resistant breast cancer and of
lung and colon cancers [270, 271].
5.4. Biomarkers of IGF Responsiveness. Stratification of
patients on the basis of biomarker measurements has been
shown to identify patients who are most likely to bene-
fit from particular forms of therapy. For example, breast
cancer patients are selected for hormone therapy based on
oestrogen receptor or progesterone receptor status [272], and
trastuzumab therapy is based on ErbB2 expression [273]. In
colorectal cancer, epidermal growth factor receptor inhibitors
such as cetuximab are of benefit only in patients with a
nonmutated KRAS gene [274, 275].
Identification of patients who would benefit from
inhibitors of the IGF signal transduction pathway is at an
early stage. Studies with figitumumab have shown greater
benefit in patients with high compared to those with low
free IGF-1 levels in both non-small-cell lung carcinoma
[276] and sarcoma [263] and a trend towards improved
response in those with higher tumour type I IGF expression
in non-small-cell lung carcinoma [254]. Other studies have
suggested that expression of components of the IGF signal
transduction pathway may help to predict responsiveness
to a type I IGF receptor antibody [277] or have focussed
on expression of IRS-1 or of the A isoform of the insulin
receptor [204, 278]. Another approach may be to use
molecular profiling to identify an IGF-responsive signature
[279]. Alternatively, greater response to figitumumab was
obtained in non-small-cell lung carcinomas with squamous
histology which indicates that some tumour subtypes may
be more responsive than others [254].
5.5. Inhibition of the Insulin Signal Transduction System. As
described above, the high degree of similarity between the
autophosphorylation catalytic domain of type I IGF and
insulin receptors has meant that the majority of tyrosine
kinase inhibitors interact with the two receptors with equiv-
alent affinity (Figure 9). The realisation that the A isoform
of the insulin receptor is expressed at high levels in many
tumour cells has altered perceptions of this dual specificity
which is viewed now by many as being advantageous.
Preclinical evidence indicates that the insulin receptor
may compensate for the therapeutic inactivation of type I IGF
receptor. Insulin receptor expression is increased in type I
IGF receptor-null mice which allows normal growth of the
animals [280] and the insulin receptor promotes resistance
to inhibitory type I IGF receptor antibodies in a transgenic
pancreatic and a mouse mammary tumour animal model
[267, 281]. Thus, an unforeseen benefit of the inhibitors that
do not discriminate between the two receptors may be a
superior clinical response.
It was expected that inhibition of the insulin receptor
would lead to toxic levels of hyperglycaemia given the
importance of the insulin receptor in the regulation of blood
glucose. However, a recent study showed that administration
of the tyrosine kinase inhibitor, BMS-536924, did not induce
significant hyperglycaemia as it does not accumulate in
muscle at levels sufficient to block insulin-stimulated glucose
uptake [282].
Metformin, the biguanide taken by diabetes mellitus type
2 patients to lower their blood glucose levels, protects them
against cancer. The exact protective mechanism is unknown
and there is no evidence to suggest that metformin would be
protective in nondiabetics. Nonetheless, data are encouraging
and suggest that further research into biguanides and their
role in cancer protection is warranted [283].There is evidence
from studies in vitro that metformin may have direct antitu-
mour activity on tumour cells [284–287]. The demonstration
that thiazolidinediones are peroxisome proliferator-activated
receptor-𝛾 (PPAR𝛾) agonists suggests that they may have
antiproliferative activity via repression of insulin receptor
expression [288].
5.6. Steroid Hormone-Responsive Cancer. A few cancers are
hormonally responsive of which the two most common are
breast and prostate. Oestrogen and androgen dependence
were identified as therapeutic targets for the treatment of
breast and prostate cancers by oophorectomy and orchidec-
tomy, respectively, before the molecular details of their
mechanisms of action were known [232, 289]. A significant
proportion of breast and prostate cancers are responsive
to oestrogens and androgens, respectively; endometrial and
ovarian cancers can respond to oestrogens and leukaemia
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responds to glucocorticoids. Current treatment targets either
the supply of steroid hormone to the tumour cells or the
interaction of the steroid hormone with its receptor.
In the context of the present review, the importance
of endocrine therapy is in its value in combination with
insulin- or IGF-targeted therapeutic strategies. The rationale
is that because steroid hormones sensitise cancer cells to the
tumour-promoting actions of insulin and IGFs, simultaneous
targeting will potentiate the insulin- and IGF-suppressant
effects. Present evidence indicates that this therapeutic
approach is most likely to be effective in breast cancer but
mayhave value also in endometrial and ovarian cancers [290–
294].
5.7. Inhibition of Steroid Synthesis. There are several dif-
ferent modalities of treatment designed to reduce oestro-
gen production. These therapies include surgical, cytotoxic
chemical- or radiotherapeutic suppression of ovarian func-
tion, or inhibition of pituitary stimulation of ovarian func-
tion in pre- or perimenopausal women. Oestrogen pro-
duction may be prevented by enzyme inhibition: 17 𝛼-
hydroxylase inhibitors such as abiraterone and orteronel
prevent conversion of pregnenolone and progesterone into
androstenedione, 5 𝛼-reductase inhibitors such as finasteride
and dutasteride prevent reduction of testosterone to the
more potent dihydrotestosterone, and aromatase inhibitors
such as exemestane and anastrozole prevent aromatisation
of testosterone into oestradiol and of androstenedione into
oestrone (Figure 4(b)).
In males and postmenopausal females, adipose tissue
provides themajor source of the enzymes 17𝛽-hydroxysteroid
dehydrogenase, which converts androstenedione into testos-
terone, and aromatase which converts androgens into oestro-
gens. It seems logical to suggest that the above therapies
which target steroid synthesis might be particularly effec-
tive in the obese and many diabetic individuals who have
abundant reservoirs of adipose tissue to produce the enzymes
involved in steroid production.
5.8. Competitive Inhibitors of Binding of Steroids to Their
Receptors. Steroid hormones are lipid-soluble and diffuse
across the plasma membrane to interact with intracellular or
intranuclear receptors. Responsiveness to steroid hormones
is determined by the presence of steroid hormone receptors in
the target cells of which there is at least one cognate receptor
protein for each type of steroid hormones (Figure 4(a)).
The steroid hormones bind to and activate their cognate
receptors which are ligand-dependent transcription factors
and thereby alter directly the expression of repertoires of
hormone-responsive genes.
Antioestrogens are competitive inhibitors of oestro-
gen for the oestrogen receptor (Figure 4(c)). Competitive
inhibitors can be partial oestrogen antagonists that do not
stimulate some oestrogenic effects but do stimulate other
oestrogen effects. The partial antagonist tamoxifen has been
the antioestrogen used most widely. Tamoxifen is a triph-
enylethylene derivative that binds to the oestrogen receptor
but does not induce the conformational change in the
position of helix 12 relative to the ligand binding domain that
is required for subsequent interaction with coactivators of
transcription [295]. Tamoxifen and its metabolites have both
oestrogenic and antioestrogenic activities in breast cancer
cells [296, 297]. Pure oestrogen antagonists such as the
steroidal antioestrogen, fulvestrant, have no oestrogen ago-
nist activity [298]. Antiandrogens or androgen antagonists
are the mainstay of systemic treatment of prostate cancer and
may have a role in the treatment of some epithelial ovarian
cancers. Flutamide and bicalutamide are widely used pure
antiandrogens.
5.9. Predictive Biomarkers of Responsiveness to Hormone
Therapy. Accepted predictive biomarkers of response to
oestrogen-targeted therapy are the oestrogen and proges-
terone receptors. Other oestrogen-responsive gene products
such as TFF1 have potential [299, 300]. In the context of
combination therapy with insulin- or IGF-targeted drugs,
measurement of important proteins in the IGF signal trans-
duction pathway that are known to be induced by oestrogens
would be apposite. Type I IGF receptor, IRS-1, IRS-2, and
IGF-2 have all been shown to be induced by oestrogen in
breast, and type I IGF receptor in endometrial and ovarian,
cancer cells, and should be investigated as biomarkers for
combination therapies.
6. Conclusions
Great strides have been made in understanding the patho-
physiology that underlies the association between obesity
and cancer risk. We have discussed the important contri-
butions of hyperinsulinaemia, diabetes, exogenous insulins,
and insulin-like growth factors and the influence of steroid
hormones. The evidence for the relatively greater impor-
tance of visceral than subcutaneous obesity and of local
or paracrine effects of IGFs and steroid hormones secreted
by adipose tissue is overwhelming. Surgical intervention is
effective and drugs to fight obesity by altered appetite or
metabolism are available albeit with significant side effects. As
obesity is preventable and reversible, themost effective cancer
prevention strategy should be successful encouragement of a
healthy lifestyle to control weight.
The effects of obesity and diabetes on cancer progression
are mediated by the same pathways as cancer risk. This
review has focused on insulin, insulin-like growth factors,
and how their effects may be enhanced by steroid hormones.
Conventional therapies have been used to target steroid
hormone action for many years, and new therapies are being
evaluated.Novel drugs that target the IGF signal transduction
pathway, and in some cases the insulin signal transduction
pathway in addition, have been developed and are in clinical
evaluation. It is opportune that the availability of drugs
which are predicted to be effective in cancers that arise in a
background of obesity, hyperinsulinaemia, and diabetes has
coincided with the onset of the obesity-associated cancer
epidemic.
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It is fortuitous also that the onset of epic morbidity
induced by altered hormonal balance and homeostasis dis-
ruption has been paralleled by enormous advances in our
appreciation of the molecular mechanisms that underlie
the interactions of insulin and IGFs with their receptors
and their subsequent actions. Formerly, the distinctions
between insulin, IGF-1, and IGF-2 and the biological effects
that they stimulated via their cognate receptors were clear.
We appreciate now that there is considerable redundancy
and cross-interaction and that the same signal transduction
proteins are activated by all three ligands. In malignant cells,
high local IGF-2 concentrations, isoform A of the insulin
receptor and hybrid receptors contribute to the significant
insulin- and IGF-dependency. The ability of the malignant
cells to respond to endogenous hyperinsulinaemia or to ther-
apeutically induced hyperinsulinaemia or to the high local
concentrations of IGF-1 and IGF-2 secreted from visceral
adipose tissue in the case of endometrial and oesophageal
cells or from mammary adipose tissue in the case of breast
cells will be influenced by increased expression of isoform
A of the insulin receptor and the type I IGF receptor. The
biological response to the ligand is determined by the target
cell as much or more than by which of the three ligands
interacting with which receptor. The response of the target
cell is dictated by the spectrum of proteins expressed within
the cell which is programmed during differentiation. Thus,
an endometrial, oesophageal, or breast cell will respond
differently to the hormonal message of hyperinsulinaemia
than will a liver or skeletal muscle cell; a mitogenic or cell
survival signal will be transduced instead of glucose uptake
and glycogenesis.
Increased knowledge about the underlying reasons for
the increased risk associated with obesity, the metabolic syn-
drome, and diabetes should alert clinicians to the possibility
that cancers that arise in obese or diabetic individuals are
more likely to be driven by the aforementioned. As drugs
improve and knowledge about effective biomarkers increases,
appropriate and effective stratification of patients will become
a reality. Surgeons and oncologists should be made aware of
the likely pathways that drive the progression of cancers that
arise in the obese, and in those with diabetes mellitus type
2, to ensure that they request appropriate tests and prescribe
appropriate therapies.
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